0001121702-22-000039.txt : 20220810 0001121702-22-000039.hdr.sgml : 20220810 20220810161059 ACCESSION NUMBER: 0001121702-22-000039 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: YIELD10 BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001121702 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PLASTIC PRODUCTS [3080] IRS NUMBER: 043158289 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33133 FILM NUMBER: 221151933 BUSINESS ADDRESS: STREET 1: 19 PRESIDENTIAL WAY STREET 2: SUITE 201 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 617-583-1700 MAIL ADDRESS: STREET 1: 19 PRESIDENTIAL WAY STREET 2: SUITE 201 CITY: WOBURN STATE: MA ZIP: 01801 FORMER COMPANY: FORMER CONFORMED NAME: METABOLIX, INC. DATE OF NAME CHANGE: 20060717 FORMER COMPANY: FORMER CONFORMED NAME: METABOLIX INC DATE OF NAME CHANGE: 20000810 10-Q 1 yten-20220630.htm 10-Q yten-20220630
000112170212/312022Q2FALSE00011217022022-01-012022-06-3000011217022022-08-05xbrli:shares00011217022022-06-30iso4217:USD00011217022021-12-31iso4217:USDxbrli:shares0001121702us-gaap:GrantMember2022-04-012022-06-300001121702us-gaap:GrantMember2021-04-012021-06-300001121702us-gaap:GrantMember2022-01-012022-06-300001121702us-gaap:GrantMember2021-01-012021-06-3000011217022022-04-012022-06-3000011217022021-04-012021-06-3000011217022021-01-012021-06-3000011217022020-12-3100011217022021-06-300001121702us-gaap:CommonStockMember2022-03-310001121702us-gaap:AdditionalPaidInCapitalMember2022-03-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001121702us-gaap:RetainedEarningsMember2022-03-3100011217022022-03-310001121702us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001121702us-gaap:CommonStockMember2022-04-012022-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001121702us-gaap:RetainedEarningsMember2022-04-012022-06-300001121702us-gaap:CommonStockMember2022-06-300001121702us-gaap:AdditionalPaidInCapitalMember2022-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001121702us-gaap:RetainedEarningsMember2022-06-300001121702us-gaap:CommonStockMember2021-03-310001121702us-gaap:AdditionalPaidInCapitalMember2021-03-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001121702us-gaap:RetainedEarningsMember2021-03-3100011217022021-03-310001121702us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001121702us-gaap:CommonStockMember2021-04-012021-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001121702us-gaap:RetainedEarningsMember2021-04-012021-06-300001121702us-gaap:CommonStockMember2021-06-300001121702us-gaap:AdditionalPaidInCapitalMember2021-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001121702us-gaap:RetainedEarningsMember2021-06-300001121702us-gaap:CommonStockMember2021-12-310001121702us-gaap:AdditionalPaidInCapitalMember2021-12-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001121702us-gaap:RetainedEarningsMember2021-12-310001121702us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001121702us-gaap:CommonStockMember2022-01-012022-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001121702us-gaap:RetainedEarningsMember2022-01-012022-06-300001121702us-gaap:CommonStockMember2020-12-310001121702us-gaap:AdditionalPaidInCapitalMember2020-12-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001121702us-gaap:RetainedEarningsMember2020-12-310001121702us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001121702us-gaap:CommonStockMember2021-01-012021-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001121702us-gaap:RetainedEarningsMember2021-01-012021-06-300001121702yten:MichiganStateUniversityMember2022-06-300001121702yten:MichiganStateUniversityMember2021-12-31yten:segment0001121702us-gaap:EquipmentMember2022-01-012022-06-300001121702us-gaap:FurnitureAndFixturesMember2022-01-012022-06-300001121702us-gaap:ComputerSoftwareIntangibleAssetMember2022-01-012022-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2022-04-012022-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2021-04-012021-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001121702us-gaap:WarrantMember2022-04-012022-06-300001121702us-gaap:WarrantMember2021-04-012021-06-300001121702us-gaap:USTreasuryAndGovernmentMember2022-06-300001121702us-gaap:USTreasuryAndGovernmentMember2021-12-310001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001121702us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001121702us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001121702us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:FairValueMeasurementsRecurringMember2022-06-300001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001121702us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001121702us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001121702us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:FairValueMeasurementsRecurringMember2021-12-310001121702us-gaap:EmployeeStockOptionMember2022-06-300001121702us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2021-12-310001121702yten:EmployeeAndDirectorsStockOptionsMember2022-01-012022-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2022-06-3000011217022022-01-012022-01-0100011217022021-01-012021-01-01xbrli:pure00011217022021-05-242021-05-240001121702us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2021-12-310001121702us-gaap:RestrictedStockUnitsRSUMember2022-06-30utr:sqft0001121702yten:PresidentialWayWoburnMassachusettsMember2020-02-290001121702yten:PresidentialWayWoburnMassachusettsMember2016-10-012016-10-310001121702yten:PresidentialWayWoburnMassachusettsMemberyten:CJCheilJedangCorporationMember2016-10-310001121702yten:A410DowneyRoadAnd110GymnasiumPlaceMember2022-06-300001121702us-gaap:CollaborativeArrangementMember2020-11-3000011217022020-11-012020-11-300001121702us-gaap:CollaborativeArrangementMember2022-06-300001121702us-gaap:CollaborativeArrangementMember2020-11-122020-11-120001121702country:US2022-04-012022-06-300001121702country:CA2022-04-012022-06-300001121702country:US2021-04-012021-06-300001121702country:CA2021-04-012021-06-300001121702country:US2022-01-012022-06-300001121702country:CA2022-01-012022-06-300001121702country:US2021-01-012021-06-300001121702country:CA2021-01-012021-06-300001121702country:US2022-06-300001121702country:CA2022-06-300001121702country:US2021-06-300001121702country:CA2021-06-300001121702yten:PublicOfferingMember2021-02-032021-02-030001121702yten:PublicOfferingMember2021-02-030001121702yten:PublicOfferingMemberyten:SeriesBWarrantExpiringMay2027Member2022-06-300001121702us-gaap:PrivatePlacementMemberyten:SeriesBWarrantExpiringMay2027Member2022-06-300001121702yten:SeriesAWarrantExpiringDecember2022Memberyten:PublicOfferingMember2022-06-300001121702yten:WarrantExpiringJanuary2024Member2022-06-300001121702yten:WarrantExpiringSeptember2024Member2022-06-3000011217022022-05-192022-05-190001121702us-gaap:EmployeeStockOptionMember2021-12-310001121702us-gaap:WarrantMember2022-06-300001121702us-gaap:WarrantMember2021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 2022

OR

☐      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                to                
Commission file number 001-33133
YIELD10 BIOSCIENCE, INC.
Delaware04-3158289
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
19 Presidential Way
Woburn, MA
01801
(Address of principal executive offices)(Zip Code)
(617) 583-1700
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockYTEN
The Nasdaq Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ý  No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý  No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” "accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated filerý Smaller reporting companyý
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No ý

The number of shares outstanding of the registrant’s common stock as of August 5, 2022 was 4,914,121.

1

Yield10 Bioscience, Inc.
Form 10-Q
For the Quarter Ended June 30, 2022

Table of Contents

Page
Item
Item

2

PART I.  FINANCIAL INFORMATION
ITEM 1.  CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands, except share and per share data)

June 30,
2022		December 31,
2021
Assets
Current Assets:
Cash and cash equivalents$3,180 $5,329 
Short-term investments6,978 10,661 
Accounts receivable35 164 
Unbilled receivables28 34 
Prepaid expenses and other current assets483 436 
Total current assets10,704 16,624 
Restricted cash264 264 
Property and equipment, net895 890 
Right-of-use assets2,162 2,354 
Other assets248 283 
Total assets$14,273 $20,415 
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable$24 $83 
Accrued expenses1,059 1,136 
Current portion of lease liabilities544 514 
Total current liabilities1,627 1,733 
Lease liabilities, net of current portion2,375 2,656 
Total liabilities4,002 4,389 
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding
— — 
Common stock ($0.01 par value per share); 60,000,000 shares authorized at June 30, 2022 and December 31, 2021; 4,901,246 and 4,881,851 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively
49 49 
Additional paid-in capital403,347 402,283 
Accumulated other comprehensive loss(220)(175)
Accumulated deficit(392,905)(386,131)
Total stockholders’ equity10,271 16,026 
Total liabilities and stockholders’ equity$14,273 $20,415 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
3

YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(in thousands, except share and per share data)
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Revenue:
Grant revenue$103 $174 $252 $370 
Total revenue103 174 252 370 
Expenses:
Research and development2,016 1,651 3,779 2,967 
General and administrative1,523 1,604 3,230 3,036 
Total expenses3,539 3,255 7,009 6,003 
Loss from operations(3,436)(3,081)(6,757)(5,633)
Other income (expense):
Other income (expense), net2 — 1 (1)
Total other income (expense)2 — 1 (1)
Loss from operations before income taxes(3,434)(3,081)(6,756)(5,634)
Income tax provision(9)(11)(18)(19)
Net loss$(3,443)$(3,092)$(6,774)$(5,653)
Basic and diluted net loss per share$(0.70)$(0.64)$(1.38)$(1.23)
Number of shares used in per share calculations:
Basic and diluted4,900,298 4,868,156 4,894,638 4,583,723 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
4

YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
UNAUDITED
(in thousands)

Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Net loss:$(3,443)$(3,092)$(6,774)$(5,653)
Other comprehensive loss
Change in unrealized loss on investments(1)— (22)1 
Change in foreign currency translation adjustment, net of income tax(26)6 (23)5 
Total other comprehensive income (loss)(27)6 (45)6 
Comprehensive loss$(3,470)$(3,086)(6,819)$(5,647)


The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
5

YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
UNAUDITED
(in thousands)

Six Months Ended
   June 30,
 20222021
Cash flows from operating activities  
Net loss$(6,774)$(5,653)
Adjustments to reconcile net loss to cash used in operating activities:  
Depreciation and amortization128 108 
Charge for 401(k) company common stock match76 69 
Stock-based compensation1,011 739 
Non-cash lease expense192 175 
Deferred income tax provision19 14 
Changes in operating assets and liabilities:  
Accounts receivable129 10 
Unbilled receivables6 (11)
Prepaid expenses and other assets(37)24 
Accounts payable(59)41 
Accrued expenses(80)(69)
Lease liabilities(251)(223)
Net cash used in operating activities(5,640)(4,776)
Cash flows from investing activities  
Purchase of property and equipment(133)(136)
Purchase of investments(710)(3,891)
Proceeds from the maturity of short-term investments4,371 5,250 
Net cash provided by investing activities3,528 1,223 
Cash flows from financing activities  
Proceeds from warrants exercised— 3,856 
Proceeds from public offering, net of issuance costs— 11,993 
Taxes paid on employees' behalf related to vesting of stock awards(14)(83)
Net cash (used in) provided by financing activities(14)15,766 
Effect of exchange rate changes on cash, cash equivalents and restricted cash(23)5 
Net (decrease) increase in cash, cash equivalents and restricted cash(2,149)12,218 
Cash, cash equivalents and restricted cash at beginning of period5,593 3,687 
Cash, cash equivalents and restricted cash at end of period$3,444 $15,905 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
6

YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
UNAUDITED
(In thousands, except share amounts)

Three Months Ended June 30, 2022
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
SharesPar ValueAccumulated Deficit
Balance, March 31, 20224,893,403 $49 $402,817 $(193)$(389,462)$13,211 
Stock-based compensation expense— — 489 — — 489 
Issuance of common stock for 401(k) match7,843 — 41 — — 41 
Effect of foreign currency translation and unrealized loss on investments— — — (27)— (27)
Net loss— — — — (3,443)(3,443)
Balance, June 30, 20224,901,246 $49 $403,347 $(220)$(392,905)$10,271 


Three Months Ended June 30, 2021
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
SharesPar ValueAccumulated Deficit
Balance, March 31, 20214,865,335 $49 $400,865 $(159)$(377,661)$23,094 
Stock-based compensation expense— — 414 — — 414 
Issuance of common stock for 401(k) match3,131 — 40 — — 40 
Effect of foreign currency translation and unrealized loss on investments— — — 6 — 6 
Net loss— — — — (3,092)(3,092)
Balance, June 30, 20214,868,466 $49 $401,319 $(153)$(380,753)$20,462 


7

Six Months Ended June 30, 2022
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
SharesPar ValueAccumulated Deficit
Balance, December 31, 20214,881,851 $49 $402,283 $(175)$(386,131)$16,026 
Stock-based compensation expense— — 1,012 — — 1,012 
Issuance of common stock for 401(k) match12,917 — 66 — — 66 
Issuance of common stock for restricted units6,478 — — — — — 
Taxes paid on employees' behalf related to vesting of stock awards— — (14)— — (14)
Effect of foreign currency translation and unrealized loss on investments— — — (45)— (45)
Net loss— — — — (6,774)(6,774)
Balance, June 30, 20224,901,246 $49 $403,347 $(220)$(392,905)$10,271 


Six Months Ended June 30, 2021
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
SharesPar ValueAccumulated Deficit
Balance, December 31, 20203,334,048 $33 $384,758 $(159)$(375,100)$9,532 
Stock-based compensation expense— — 749 — — 749 
Issuance of common stock for 401(k) match6,890 — 62 — — 62 
Issuance of common stock for warrant exercises481,973 5 3,851 — — 3,856 
Issuance of common stock for restricted units5,555 — — — — — 
Taxes paid on employees' behalf related to vesting of stock awards— — (83)— — (83)
Issuance of common stock in connection with stock offering, net of offering costs1,040,000 11 11,982 — — 11,993 
Effect of foreign currency translation and unrealized loss on investments— — — 6 — 6 
Net loss— — — — (5,653)(5,653)
Balance, June 30, 20214,868,466 $49 $401,319 $(153)$(380,753)$20,462 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
8

YIELD10 BIOSCIENCE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
UNAUDITED

(All dollar amounts, except share and per share amounts, are stated in thousands)
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address:
•petroleum replacement markets, in which the Company is developing Camelina oil for use as a biofuel feedstock and PHA Bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and
•food and nutrition markets, in which the Company is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets.
Yield10 also plans to license yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, Massachusetts, and has an Oilseed Center of Excellence located in Saskatoon, Saskatchewan, Canada. Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding.
    The accompanying condensed consolidated financial statements are presented in U.S. dollars, are unaudited, and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statement of the financial position as of June 30, 2022 and December 31, 2021, and for the results of operations for the interim periods ended June 30, 2022 and June 30, 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2022.
The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including the three and six months ended June 30, 2022.
    As of June 30, 2022, the Company held unrestricted cash, cash equivalents and investments of $10,158. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed consolidated financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on our current cash forecast, we have determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these condensed consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.
9

    If the Company issues equity or debt securities to raise additional funds in the future, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.
In February 2022, Russia initiated a military offensive in Ukraine which has resulted in significant uncertainty in the commodities market. The scope, intensity, duration and outcome of the ongoing war, resulting sanctions and resulting future market disruptions is uncertain and its continuation or escalation may have a material adverse effect on the Company. Ukraine, and the Black Sea region in general, are a major exporter of wheat and corn to the world, and the disruption of supply could cause volatility in prices and margins of these commodities and related products. Ukraine is also the largest supplier of sun seed and sun oil in the world which cannot be completely replaced from other geographic regions. The conflict in Ukraine has created disruptions in global supply chains and is expected to create dislocations of key agricultural commodities. While Yield10 has no direct business operations or assets within either Ukraine or Russia, the Company's plans and operating results could be adversely affected by a number of factors, including the crop growing decisions made by farmers in the U.S., Canada and South America as a consequence of supply shortages and rising commodity prices. These rising prices may negatively impact the Company's ability to contract suitable acreage for future crop trials or could delay its plans to commercialize Yield10's first Camelina plant varieties.
The Company’s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions and uncertainties. For instance, in July 2022, the U.S. Bureau of Labor Statistics reported that the Consumer Price Index for All Urban Consumers increased 9.1 percent, the largest 12-month increase since the 12-month period ending November 1981. If the inflation rate continues to increase, for example due to increases in the costs of labor and supplies, it will affect the Company's expenses and it might make it difficult for the Company to continue its research and development. Inflation could also adversely affect the ability of growers to enter into and fulfill their obligations under Camelina grain production agreements with the Company.
The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the evolving nature of the COVID-19 pandemic and the global responses to it, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for future periods.
2. ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the FASB Accounting Standards Codification ("ASC"). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:
10

June 30,
2022		December 31,
2021
Cash and cash equivalents$3,180 $5,329 
Restricted cash264 264 
Total cash, cash equivalents and restricted cash$3,444 $5,593 
Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at June 30, 2022 and December 31, 2021 consists primarily of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.
Investments
The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments.
Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign Currency Translation
The functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Comprehensive Loss
Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.
The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as
11

well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.
At June 30, 2022, all of the Company's accounts and unbilled receivables of $63 were due from Michigan State University ("MSU") for support to a Department of Energy ("DOE") funded grant under which the Company serves as a subcontractor. The Company believes these receivables have a low risk of default. At December 31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support to the DOE grant.

Fair Value Measurements
The carrying amounts of the Company's financial instruments as of June 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 5 for further discussion on fair value measurements.
Segment Information
The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:
Asset DescriptionEstimated Useful Life (years)
Equipment3
Furniture and fixtures5
Software3
Leasehold improvementsShorter of useful life or term of lease
Lease Accounting
As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.
12

Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.
Grant Revenue
The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at June 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.
Research and Development
All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense.
General and Administrative Expenses
The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company.
Intellectual Property Costs
The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations.
Stock-Based Compensation
All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 7 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.
Recent Accounting Standards
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date.
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022.
The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same
13

effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements.

3. BASIC AND DILUTED NET LOSS PER SHARE
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards and warrants.
The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:
As of June 30,
 20222021
Options949,884 531,946 
Restricted Stock Awards54,250 18,862 
Warrants1,290,273 2,361,726 
Total2,294,407 2,912,534 

4. INVESTMENTS
Investments consist of the following at June 30, 2022 and December 31, 2021:
Accumulated Cost at June 30, 2022UnrealizedMarket Value at June 30, 2022
Gain(Loss)
Short-term investments
     U.S. government and agency securities$7,008 $— $(30)$6,978 
          Total$7,008 $— $(30)$6,978 
Accumulated Cost at December 31, 2021UnrealizedMarket Value at December 31, 2021
Gain(Loss)
Short-term investments
     U.S. government and agency securities$10,669 $— $(8)$10,661 
          Total$10,669 $— $(8)$10,661 
All investments are classified as available for sale as of June 30, 2022 and December 31, 2021.
14

5. FAIR VALUE MEASUREMENTS
The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.
The Company’s financial assets classified as Level 2 at June 30, 2022 and December 31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of June 30, 2022 and December 31, 2021.
The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.
Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets		Significant other
observable inputs		Significant
unobservable  inputs		Balance as of
Description(Level 1)(Level 2)(Level 3)June 30, 2022
Cash equivalents:
Money market funds
$2,061 $— $— $2,061 
Short-term investments:
U.S. government and agency securities
— 6,978 — 6,978 
Total assets$2,061 $6,978 $— $9,039 

Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets		Significant other
observable inputs		Significant
unobservable  inputs		Balance as of
Description(Level 1)(Level 2)(Level 3)December 31, 2021
Cash equivalents:
Money market funds
$4,878 $— $— $4,878 
Short-term investments:
U.S. government and agency securities
— 10,661 — 10,661 
Total assets$4,878 $10,661 $— $15,539 
There were no transfers of financial assets between category levels during the three and six months ended June 30, 2022 and the three and six months ended June 30, 2021.
15

6. ACCRUED EXPENSES
Accrued expenses consisted of the following at:
June 30,
2022		December 31,
2021
Employee compensation and benefits$381 $452 
Leased facilities61 71 
Professional services267 264 
Field trials and related expenses215 97 
Other135 252 
Total accrued expenses$1,059 $1,136 

7. STOCK-BASED COMPENSATION
Expense Information for Employee and Non-Employee Stock Awards
The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors of $488 and $1,011 for the three and six months ended June 30, 2022 and $415 and $739 for the three and six months ended June 30, 2021. At June 30, 2022, there was approximately $4,009 of unvested awards not yet recognized as compensation expense.
The compensation expense related to unvested stock awards is expected to be recognized over a remaining weighted average period of 2.80 years.
Stock Options
A summary of option activity for the six months ended June 30, 2022 is as follows:
Number of
Shares		Weighted Average
Exercise Price
Outstanding at December 31, 2021722,765 $19.22 
Granted227,224 $3.85 
Expired(105)$5,849.14 
Outstanding at June 30, 2022949,884 $14.90 
Options exercisable at June 30, 2022318,699 $30.12 
In accordance with the terms of the Company's 2018 Stock Option and Incentive Plan ("2018 Stock Plan"), effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of 244,092 shares and 166,702 shares, respectively, to the 2018 Stock Plan, which represented 5% of the Company's outstanding common stock on the day prior to each increase. At its annual meeting of stockholders on May 24, 2021, stockholders approved an amendment to the 2018 Stock Plan to add 300,000 more shares to the plan. As of June 30, 2022, 29,964 shares remain available to be awarded from the 2018 Stock Plan.
Restricted Stock Units
The Company records stock compensation expense for restricted stock units ("RSUs") on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date fair market value. As RSUs vest, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount from the common stock issuable at the vest date. During the six months ended June 30, 2022, 9,430 employee RSUs vested, of which 2,952 common shares with a total market value of $13 were withheld to pay employee tax withholding.
16

A summary of RSU activity for the six months ended June 30, 2022 is as follows:
Number of RSUsWeighted Average Remaining Contractual Life (years)
Outstanding at December 31, 20219,430 
Awarded54,250 
Released(9,430)
Outstanding at June 30, 202254,250 0.36

8. LEASES
Maturity Analysis of Lease Liabilities
The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At June 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows:
Year ended December 31,Undiscounted Cash Flows
2022 (July to December)$367 
2023749 
2024771 
2025793 
2026747 
Total undiscounted future lease payments3,427 
Amount of lease payments representing interest(512)
Total lease liabilities$2,915 
     Short-term lease liability$544 
     Long-term lease liability$2,371 
Quantitative Disclosure of Lease Costs
Three Months Ended
   June 30,		Six Months Ended
  June 30,
2022202120222021
Lease cost:
Operating lease cost$151 $151 $303 $303 
Short-term lease cost183 169 332 326 
Sublease income(153)(146)(295)(320)
Total lease cost, net$181 $174 $340 $309 
Other information as of:June 30, 2022December 31, 2021
Weighted-average remaining lease term (years)4.44.9
Weighted-average discount rate7.25%7.25%
Real Estate Leases
    During 2016, the Company entered into a lease agreement, as amended, for its headquarters pursuant to which the Company leases 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease agreement will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and
17

operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for certain tenant improvements that resulted in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229.
In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The CJ sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,427 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.
The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 7,800 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. YOI's leases for these facilities expire on various dates through May 2023.
9. COMMITMENTS AND CONTINGENCIES
Contractual Commitments    
Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")
In November 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. The Company is paying Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $63 remains outstanding as of June 30, 2022. As part of the agreement, the Company has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. The current agreement terminates automatically on its second anniversary unless terminated earlier in accordance with the terms of the agreement.
License Agreement with the University of Missouri ("UM")
Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops. Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production. The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops.
Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone.
The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products. The Company or UM may terminate the license agreement in accordance with the terms of the agreement.
Facility Leases
The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026. See Note 8.
Litigation
From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.
18

Guarantees
    As of June 30, 2022 and December 31, 2021, the Company did not have significant liabilities recorded for guarantees.
The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of June 30, 2022 and December 31, 2021.
10. GEOGRAPHIC INFORMATION
The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled.
U.S.CanadaTotal
Three Months Ended June 30, 2022
Revenue$103 $— $103 
Three Months Ended June 30, 2021
Revenue$174 $— $174 
Six Months Ended June 30, 2022
Revenue$252 $— $252 
Six Months Ended June 30, 2021
Revenue$331 $39 $370 
Identifiable long-lived assets
June 30, 2022$752 $143 $895 
June 30, 2021$896 $53 $949 
11. CAPITAL STOCK AND WARRANTS
Common Stock
Registered Public Offerings
    On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747.
Preferred Stock
The Company's Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of $0.01 par value preferred stock.
Warrants
The following table summarizes information regarding outstanding warrants to purchase common stock as of June 30, 2022:
19

IssuanceNumber of Shares Issuable Upon Exercise of Outstanding WarrantsExercise Price Per Share of Common StockExpiration Date
November 2019 Public Offering - Series B395,528 $8.00 May 19, 2027
November 2019 Private Placement - Series B718,750 $8.00 May 19, 2027
December 2017 Public Offering - Series A160,975 $90.00 December 21, 2022
July 2017 Registered Direct Offering14,270 $201.60 January 7, 2024
Consultant750 $116.00 September 11, 2024
Total1,290,273 
Effective May 19, 2022, 1,071,453 Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued. During the six months ended June 30, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing $3,856 in cash proceeds. During the six months ended June 30, 2022, no warrants were exercised by warrant holders.
Reserved Shares
The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:
June 30,
2022		December 31,
2021
Stock Options949,884 722,765 
RSUs54,250 9,430 
Warrants1,290,273 2,361,726 
Total number of common shares reserved for future issuance2,294,407 3,093,921 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

(All dollar amounts are stated in thousands)
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipate,” “intends,” “target,” “projects,” “contemplates,” “believe,” “estimates,” “predicts,” “potential,” and “continue,” or similar words.
Although we believe that our expectations are based on reasonable assumptions within the limits of our knowledge of our business and operations, these forward-looking statements contained in this document are neither promises nor guarantees. Our business is subject to significant risk and uncertainties and there can be no assurance that our actual results will not differ materially from our expectations. These forward-looking statements include, but are not limited to, statements concerning our business plans and strategies; expected future financial results and cash requirements; statements related to the coronavirus pandemic and its potential adverse impacts; the impact from the war in Ukraine and the resulting economic and other sanctions imposed on Russia; plans for obtaining additional funding; plans and expectations that depend on our ability to continue as a going concern; and plans for development and commercialization of our Yield10 technologies. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated including, without limitation, risks related to our limited cash resources, uncertainty about our ability to secure additional funding, risks related to the execution of our business plans and strategies, risks associated with the protection and enforcement of our intellectual property rights, as well as other risks and uncertainties set forth under the caption "Risk Factors"
20

in Part I, Item 1A, of the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and in our other filings with the SEC.
The forward-looking statements and risk factors presented in this document are made only as of the date hereof and we do not intend to update any of these risk factors or to publicly announce the results of any revisions to any of our forward-looking statements other than as required under the federal securities laws.
Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to "Yield10 Bioscience," "Yield10," "we," "our," "us," "our company" or "the company" refer to Yield10 Bioscience, Inc., a Delaware corporation, and its subsidiaries.
Overview
    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address:
•petroleum replacement markets, in which we are developing Camelina oil for use as a biofuel feedstock and PHA Bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and
•food and nutrition markets, in which we are developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets.
Our commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from our development pipeline which offer improved on-farm performance that we anticipate will lead to increased acreage adoption and seed product revenue. We also plan to create additional value for our shareholders by licensing yield and seed oil traits from our pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola.
We intend to begin small scale commercial Camelina grain production this fall for the renewable diesel market. Currently, we are using third-party growers for seed multiplication of our winter Camelina plant varieties. These plants will be harvested this summer and shipped to a commercial seed conditioner for processing and packaging before being provided to farmers for planting later this fall. Yield10's commercial team is in the process of establishing an initial grower network for this first production of Camelina grain that will be harvested in the spring of 2023 and sold to renewable diesel manufacturers. We anticipate that future acreage under contract for the production of Camelina grain will expand over time as we increase our grower network and ramp up commercial operations for both spring and winter growing seasons.
Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada.
Government Grants
On February 26, 2021, Yield10 Oilseeds Inc. ("YOI"), the Company’s wholly-owned Canadian research subsidiary, received a research grant through the Industrial Research Assistance Program administered by National Research Council Canada ("NRC"). The objective of the grant was to provide financial research assistance to innovative, early-stage small and medium-sized enterprises. Under the terms of the agreement, NRC agreed to contribute up to a maximum of $39 for payroll costs incurred by YOI during the period from December 20, 2020 to March 13, 2021. During the first quarter of 2021, YOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award.
During 2018, we entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy ("DOE") funded grant entitled "A Systems Approach to Increasing Carbon Flux to Seed Oil." Our participation under this five-year grant has been awarded incrementally on an annual basis with the first year commencing on September 15, 2017. Cumulative funding for this sub-award in the amount of $2,957 has been appropriated by the U.S. Congress through the final contractual year ending in September 2022. During the three and six months ended June 30, 2022, we recognized $103 and $252, respectively, from the sub-award. During the three and six months ended June 30, 2021, we recognized $174 and $331 in grant revenue, respectively, from the sub-award.
As of June 30, 2022, proceeds of $258 remain to be recognized through the end of the final contractual year under our MSU sub-award as shown in the table below. This includes amounts for reimbursement to our subcontractors, as well as reimbursement for our employees’ time, benefits and other expenses related to future performance.
21

Program TitleFunding
Agency		Total Government Funded AppropriationsTotal revenue recognized through June 30, 2022Remaining amount to be recognized as of June 30, 2022Contract/Grant
Expiration
Subcontract from Michigan State University project funded by DOE entitled "A Systems Approach to Increasing Carbon Flux to Seed Oil"Department of Energy$2,957 $2,699 $258 September 2022
Funding from National Research Council Canada through its Industrial Research Assistance Program (NRC-IRAP) entitled "Innovation Assistance Program - Round 2.5"National Research Council Canada39 39 — March 2021
Total$2,996 $2,738 $258 
Critical Accounting Estimates and Judgments
The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP for interim financial information. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, stock-based and performance-based compensation, measurement of right-of-use assets and lease liabilities, the recognition of lease expense and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The critical accounting policies and the significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022, were consistent with those discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates and Judgments.”
Results of Operations
Comparison of the Three Months Ended June 30, 2022 and 2021
Revenue 
Three Months Ended
June 30,
 20222021Change
Grant revenue$103 $174 $(71)
Grant revenue was $103 and $174 for the three months ended June 30, 2022 and June 30, 2021, respectively.  All of the grant revenue recorded during these two periods was derived from the Company's DOE sub-award with MSU. Grant revenue was lower during the three months ended June 30, 2022 compared to the three months ended June 30, 2021 as a result of allocating greater resources to support other Camelina research and development initiatives.
We anticipate that grant revenue will decrease during the year ended December 31, 2022 in comparison to the year ended December 31, 2021, as a result of lower grant appropriations remaining to be earned during the final contract year of our MSU sub-award that ends in September 2022. We currently cannot assess whether additional U.S. or Canadian government research grants will be awarded to us during 2022. We plan to begin contracting with growers for small scale Camelina grain production this fall to supply the renewable diesel fuel market. Harvest of this first commercial grain production is expected to occur in the spring of 2023, at which time we anticipate that we will begin to recognize grain revenue in amounts scaled to the number of acres under contract. Future grain revenues will be based, among other things, on our ability to scale up commercial seed production, engage with growers and enter into offtake agreements with customers in the renewable diesel market.
22

Expenses
Three Months Ended
June 30,
 20222021Change
Research and development expenses$2,016 $1,651 $365 
General and administrative expenses1,523 1,604 (81)
Total expenses$3,539 $3,255 $284 
Research and Development Expenses
Research and development expenses increased from $1,651 during the three months ended June 30, 2021 to $2,016 during the three months ended June 30, 2022. The $365, or 22 percent increase, is primarily due to higher employee compensation and benefit expenses and costs associated with pre-commercial Camelina seed production. Employee compensation and benefits increased by $150 from $943 during the three months ended June 30, 2021 to $1,093 during the three months ended June 30, 2022, and was primarily the result of a $200 increase in payroll expense generated from annual employee compensation increases and our hiring of additional staff during 2021 and early 2022. Offsetting a portion of this increase in payroll expense was a reduction in recruiting-related expenses of $85 incurred during the three months ended June 30, 2021 that did not recur during the three months ended June 30, 2022. During the three months ended June 30, 2022, we incurred $128 in expense for pre-commercial Camelina seed production, including seed multiplication, cleaning, treatment and storage costs. We did not have similar expenses during the three months ended June 30, 2021.
Based on current planning and forecasting, we anticipate that our research and development expenses during the year ended December 31, 2022 will continue at levels above those incurred during the year ended December 31, 2021, as we continue our efforts to develop and commercialize Camelina plant varieties for the following markets: feedstock oil for renewable diesel, PHA bioplastics, omega-3 oil for nutraceuticals and aquaculture fish feed and as a protein meal to be used in animal feed markets. The increased expenses will include employee compensation and benefits from recent and future personnel hiring, seed scale up operations and pre-commercial Camelina activities. Our forecast related to research and development expense is subject to change and may be impacted by our ability to raise additional cash to support our planned operations, the potential impact of the COVID-19 pandemic or the advent of new third-party collaborations or other business opportunities that could alter our plans.
General and Administrative Expenses
General and administrative expenses for the three months ended June 30, 2022 and June 30, 2021 decreased by $81 from $1,604 to $1,523. The 5 percent decrease is primarily due to reductions in professional legal and accounting fees related to patent filings and maintenance as well as corporate tax services provided by outside firms.
Based on current planning and forecasting, we anticipate that our general and administrative expenses during the year ended December 31, 2022 will be slightly higher than expenses incurred during the year ended December 31, 2021. Our forecast related to general and administrative expense is subject to change and may be impacted by our ability to raise additional cash to support our plans, the potential impact of the COVID-19 pandemic or new third-party collaborations or other business opportunities that could alter our plans.
Other Income (Expense), Net 
Three Months Ended
June 30,
 20222021Change
Other income (expense), net$2 $— $2 
Other Income (Expense), net
    Other income (expense) for the three months ended June 30, 2022 and June 30, 2021 were derived primarily from investment income earned from the Company's cash equivalents and investments offset by interest expense and investment management fees incurred during the period.
23

Comparison of the Six Months Ended June 30, 2022 and 2021
Revenue 
Six Months Ended
June 30,
 20222021Change
Grant revenue$252 $370 $(118)
Grant revenue was $252 and $370 for the six months ended June 30, 2022 and June 30, 2021, respectively.  All of the grant revenue recorded during the six months ended June 30, 2022 was derived from the Company's DOE sub-award with MSU. During the six months ended June 30, 2021, grant revenue of $331 and $39 was recognized from the DOE sub-award and the short-term NRC grant that was awarded in February 2021, respectively.
Expenses
Six Months Ended
June 30,
 20222021Change
Research and development expenses$3,779 $2,967 $812 
General and administrative expenses3,230 3,036 194 
Total expenses$7,009 $6,003 $1,006 
Research and Development Expenses
Research and development expenses increased from $2,967 during the six months ended June 30, 2021 to $3,779 during the six months ended June 30, 2022. The $812, or 27 percent year-to-date increase, is primarily due to higher employee compensation and benefits, third-party research services, costs associated with pre-commercial Camelina seed production, and facility-related expenses. Employee compensation and benefits increased by $343 from $1,812 during the six months ended June 30, 2021 to $2,155 during the six months ended June 30, 2022. The increase is primarily the result of a $324 increase in payroll expenses generated from annual employee compensation increases, our hiring of additional staff during 2021 and 2022. Recruiting related expenses were $110 lower during the six months ended June 30, 2022 than in the first six months of 2021. Third-party research service expense also increased by $185 during the six months ended June 30, 2022 in comparison to the six months ended June 30, 2021, and was primarily the result of work performed for crop trials, Camelina plant variety improvements, DNA sequencing and other analytical work undertaken for regulatory purposes. During the six months ended June 30, 2022, we also incurred $128 in expense for pre-commercial Camelina seed production, including seed multiplication, cleaning, treatment and storage costs. We did not have similar expenses during the six months ended June 30, 2021.
General and Administrative Expenses
General and administrative expenses for the six months ended June 30, 2022 and June 30, 2021 increased by $194 from $3,036 to $3,230. The 6 percent year-to-date increase is primarily due to increases in employee compensation and benefits expenses. Employee compensation and benefits expense increased by $211 from $1,358 during the six months ended June 30, 2021 to $1,569 during the six months ended June 30, 2022, and is primarily the result of a $101 increase in payroll expenses generated from annual employee compensation increases and our hiring of additional staff during 2021. During the six months ended June 30, 2022, stock-based compensation also increased by $186 due to employee stock awards issued during the past year. Recruiting expenses were down $43 during the six months ended June 30, 2022 compared to the first six months of 2021.
Other Income (Expense), Net 
Six Months Ended
June 30,
 20222021Change
Other income (expense), net$1 $(1)$2 
24

Other Income (Expense), net
    Other income (expense) for the six months ended June 30, 2022 and June 30, 2021 were derived primarily from investment income earned from the Company's cash equivalents and investments offset by interest expense and investment management fees incurred during the period.
Liquidity and Capital Resources
Currently, we require cash to fund our working capital needs, to purchase capital assets, and to pay our operating lease obligations and other operating costs. The primary sources of our liquidity have historically included equity financings, government funded research grants and income earned on cash and investments.
Since our inception, we have incurred significant expenses related to our research, development and product commercialization efforts. With the exception of 2012, we have recorded losses since our initial founding, including the three and six months ended June 30, 2022. As of June 30, 2022, we had an accumulated deficit of $392,905. Our unrestricted cash, cash equivalents and investments are held primarily for working capital purposes and as of June 30, 2022, totaled $10,158 compared to cash, cash equivalents and investments of $15,990 at December 31, 2021. As of June 30, 2022, we had restricted cash of $264, consisting of $229 held in connection with the lease agreement for our Woburn, Massachusetts facility and $35 held in connection with our corporate credit card program. As of June 30, 2022, we continued to have no outstanding debt.
Investments are made in accordance with our corporate investment policy, as approved by our Board of Directors. The primary objective of this policy is to preserve principal. Consequently, our investments are limited to high quality corporate debt, U.S. Treasury bills and notes, money market funds, bank debt obligations, municipal debt obligations and asset-backed securities. The policy establishes maturity limits, concentration limits, and liquidity requirements. As of June 30, 2022, we were in compliance with this policy.
Material Cash Requirements
We currently anticipate net cash usage of $12,000 to $12,500 to fund operations during the full year 2022, including our expanded research and development activities and our preparations for the future commercial launch of our Camelina products.
We routinely enter into contractual commitments with third parties to support our operating activities. The more significant of these commitments includes real estate operating leases for our office, laboratory and greenhouse facilities located in the U.S. and Canada. In addition, we typically enter into annual premium funding arrangements through our insurance broker that allows us to spread the payment of our directors' and officers' liability and other business insurance premiums over the terms of the policies. Our material commitments also include annual arrangements with third party growers located in North and South America for the execution of crop trials and seed scale-up activities to further our trait development goals and to progress the commercial development of our Camelina plant varieties. The aggregate cost of these contracted crop activities is substantial. From time-to-time, we also enter into exclusive research licensing and collaboration arrangements with third parties for the development of intellectual property related to trait development. These long-term agreements typically include initial licensing payments and future contingent milestone payments associated with regulatory filings and approvals as well as potential royalty payments based on future product sales. Generally, these licensing arrangements contain early termination provisions within the terms of the respective agreements.
The Company has no off-balance sheet arrangements as defined in Item 303(b) of Regulation S-K of the Securities Exchange Act of 1934.
Going Concern
We follow the guidance of ASC Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are available to be issued. Based on our current cash forecast, we expect that our present capital resources will not be sufficient to fund our planned operations for at least that period of time, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. Our ability to continue operations after our current cash resources are exhausted will depend upon our ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional government research grants or collaborative arrangements with third parties, as to which no assurances can be given. We do not know whether additional financing will be available on terms favorable or acceptable to us when needed, if at all. If
25

additional funds are not available when required, we will be forced to curtail our research efforts, explore strategic alternatives and/or wind down our operations and pursue options for liquidating our remaining assets, including intellectual property and equipment.
If we issue equity or debt securities to raise additional funds, (i) we may incur fees associated with such issuances, (ii) our existing stockholders will experience dilution from the issuance of new equity securities, (iii) we may incur ongoing interest expense and be required to grant a security interest in our assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. In addition, utilization of our net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986 due to ownership changes resulting from future equity financing transactions. If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our potential products or proprietary technologies or grant licenses on terms that are not favorable to us.
Cash Usage During the Six Months Ended June 30, 2022
Net cash used for operating activities during the six months ended June 30, 2022 was $5,640, compared to net cash used for operating activities during the six months ended June 30, 2021 of $4,776. Net cash used for operating activities during the six months ended June 30, 2022 primarily reflects the net loss of $6,774, cash payments made to reduce lease liabilities of $251 and our payment of 2021 bonus compensation of $378 during early 2022. Non-cash charges offsetting a portion of the net loss include depreciation and amortization expense of $128, our 401(k) matching contribution in common stock of $76, stock-based compensation expense of $1,011, and non-cash lease expense of $192. Net cash used for operating activities during the six months ended June 30, 2021 was $4,776 and primarily reflects the net loss of $5,653, cash payments made to reduce lease liabilities and to pay 2020 bonus compensation of $223 and $460, respectively. Non-cash charges offsetting a portion of the net loss included depreciation and amortization expense of $108, our 401(k) matching contribution in common stock of $69, stock-based compensation expense of $739, and non-cash lease expense of $175.
Net cash of $3,528 was provided by investing activities during the six months ended June 30, 2022, primarily as a result of receiving proceeds of $4,371 from investments reaching maturity and converting into cash, partially offset by our purchase of $710 in new investments. During the six months ended June 30, 2022, we also purchased $133 in laboratory equipment. During the six months ended June 30, 2021, $1,223 in net cash was provided from investing activities. During the six months of 2021, we purchased of $136 of laboratory equipment and $3,891 in new investments, offset by cash proceeds of $5,250 from maturing investments.
Net cash of $14 was used by financing activities during the six months ended June 30, 2022, compared to net cash of $15,766 provided by financing activities during the six months ended June 30, 2021. During the six months ended June 30, 2021, we completed a public offering of 1,040,000 shares of our common stock at a price of $12.25 per share, receiving proceeds of $12,740, before issuance costs of $747. Also, during the six months ended June 30, 2021, a total of 481,973 Series A and Series B warrants issued in our November 2019 securities offering were exercised by warrant holders, providing $3,856 in cash proceeds. During the six months ended June 30, 2022, no warrants were exercised by warrant holders.
Recent Accounting Pronouncements
See Note 2, "Accounting Policies," to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a full description of recent accounting pronouncements.
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Not applicable.
ITEM 4.  CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Our management (with the participation of our Principal Executive Officer and Principal Accounting Officer) evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of June 30, 2022. Disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and communicated to management, including the Principal Executive Officer and the Principal Accounting Officer, as appropriate, to allow timely decisions regarding disclosure. Based
26

on this evaluation, our Principal Executive Officer and Principal Accounting Officer concluded that these disclosure controls and procedures are effective. 
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION
ITEM 1.  LEGAL PROCEEDINGS.
From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations.
ITEM 1A.  RISK FACTORS.
There have been no material changes to the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 25, 2022, as amended and supplemented by the risk factors described in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 11, 2022.
ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
Recent Sales of Unregistered Securities
On July 1, 2022, we issued 12,875 shares of common stock to participants in the Yield10 Bioscience, Inc. 401(k) Plan as a matching contribution. The issuance of these securities is exempt from registration pursuant to Section 3(a)(2) of the Securities Act as exempted securities.
Issuer Purchases of Equity Securities
During the three months ended June 30, 2022, there were no repurchases made by us or on our behalf, or by any “affiliated purchasers,” of shares of our common stock.
ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4.  MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5.  OTHER INFORMATION.
None.
27

ITEM 6.  EXHIBITS.
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Principal Executive Officer (filed herewith).
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Principal Financial Officer (filed herewith).
Section 1350 Certification (furnished herewith).
101.INSInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) (filed herewith).
101.SCHInline XBRL Taxonomy Extension Schema Document (filed herewith).
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith).
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document (filed herewith).
101.LABInline XBRL Taxonomy Extension Label Linkbase Document (filed herewith).
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document (file herewith).
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (filed herewith).
28



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
YIELD10 BIOSCIENCE, INC.
August 10, 2022By:/s/ OLIVER PEOPLES
Oliver Peoples
President and Chief Executive Officer
(Principal Executive Officer)
August 10, 2022By:/s/ CHARLES B. HAASER
Charles B. Haaser
Chief Accounting Officer
(Principal Financial and Accounting Officer)

29
 EX-31.1 2 ex-311x20220630.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATION
 
I, Oliver Peoples, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Yield10 Bioscience, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 10, 2022
/s/ OLIVER PEOPLES
Name:Oliver Peoples
Title:President and Chief Executive Officer
(Principal Executive Officer)

1
 EX-31.2 3 ex-312x20220630.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATION
 
I, Charles B. Haaser, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Yield10 Bioscience, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 10, 2022
/s/ CHARLES B. HAASER
Name:Charles B. Haaser
Title:Chief Accounting Officer
(Principal Financial and Accounting Officer)

1
 EX-32.1 4 ex-321x20220630.htm EX-32.1 Document

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
    In connection with the Quarterly Report on Form 10-Q of Yield10 Bioscience, Inc. (the “Company”) for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Oliver Peoples, President, Chief Executive Officer and Principal Executive Officer of the Company and Charles B. Haaser, Chief Accounting Officer and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2.The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

    This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.
 
Dated: August 10, 2022
/s/ OLIVER PEOPLES
Oliver Peoples
President and Chief Executive Officer
(Principal Executive Officer)
Dated: August 10, 2022
/s/ CHARLES B. HAASER
Charles B. Haaser
Chief Accounting Officer
(Principal Financial and Accounting Officer)

1
 EX-101.SCH 5 yten-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2106102 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2315304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2117106 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 2318305 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 2120107 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2321306 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2422408 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 2423409 - Disclosure - STOCK-BASED COMPENSATION - RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2124108 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2325307 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2426410 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2427411 - Disclosure - LEASES - Maturity Analysis of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2428412 - Disclosure - LEASES - Quantitative Disclosure of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2129109 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2430413 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2131110 - Disclosure - GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 2332308 - Disclosure - GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2433414 - Disclosure - GEOGRAPHIC INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 2134111 - Disclosure - CAPITAL STOCK AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 2335309 - Disclosure - CAPITAL STOCK AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2436415 - Disclosure - CAPITAL STOCK AND WARRANTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2437416 - Disclosure - CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 2438417 - Disclosure - CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 yten-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 yten-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 yten-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Warrants - expiration January 2024 Warrant Expiring January 2024 [Member] Warrant Expiring January 2024 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Name of Property [Domain] Name of Property [Domain] Increase (decrease) in stockholders' equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Warrants exercised (in shares) Class of Warrant Or Right, Exercised Class of Warrant Or Right, Exercised Undiscounted future lease payments Total undiscounted future lease payments Lessee, Operating Lease, Liability, to be Paid Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Income tax provision Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Leased area (in sq ft) Area of Real Estate Property Subleased area (in sq ft) Lessee, Operating Sublease, Subleased Area Lessee, Operating Sublease, Subleased Area Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Common stock ($0.01 par value per share); 60,000,000 shares authorized at June 30, 2022 and December 31, 2021; 4,901,246 and 4,881,851 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Financial Instruments [Domain] Financial Instruments [Domain] Issuance of common stock for restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of the geographic distribution of revenues and long-lived assets Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Short-term lease cost Short-Term Lease, Cost Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Private offering Private Placement [Member] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Issuance of common stock for warrant exercises Stock Issued During Period, Value, Conversion of Convertible Securities Additional paid-in capital Additional Paid in Capital, Common Stock Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Current Liabilities: Liabilities, Current [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Concentration of credit risk Concentration Risk [Line Items] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Warrants expired (in shares) Class of Warrant Or Right, Expired Class of Warrant Or Right, Expired Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive common stock excluded from the calculation of dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 410 Downey Road and 110 Gymnasium Place 410 Downey Road And 110 Gymnasium Place [Member] 410 Downey Road And 110 Gymnasium Place [Member] Weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Total assets Assets, Fair Value Disclosure Investments Investment, Policy [Policy Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent LEASES Lessee, Operating Leases [Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Market Value Short-term investments Debt Securities, Available-for-Sale Options exercisable at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Lease liabilities Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities Depreciation and amortization Depreciation, Depletion and Amortization Number of operating segments Number of Operating Segments 2022 (July to December) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Award Type [Axis] Award Type [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current portion of lease liabilities Short-term lease liability Operating Lease, Liability, Current Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Identifiable long-lived assets Property, Plant and Equipment, Net Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Schedule of investment holdings Debt Securities, Available-for-Sale [Table Text Block] Lease cost: Lease, Cost [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Employee stock option Options Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Expenses: Costs and Expenses [Abstract] Legal Entity [Axis] Legal Entity [Axis] Other income (expense), net Other Nonoperating Income (Expense) Common stock price (in dollars per share) Sale of Stock, Price Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Total liabilities Liabilities Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Geographical [Axis] Geographical [Axis] Stock-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Grant Grant [Member] Issuance of common stock in connection with stock offering, net of offering costs Stock Issued During Period, Value, New Issues Research and development Cost of Revenue Research and Development Expenses This element represents the expenses associated with internal research and development as well as research and development services conducted for others are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors; facility related expenses, depreciation and stock-based compensation related to employees and non-employees involved in the company's research and development, which also includes the costs related to revenue-producing contracts, which are recorded as research and development expenses, during the period by the entity. Leased facilities Accrued Lease Cost Accrued Lease Cost Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Non-cash lease expense Noncash Lease Expense (Income) Noncash Lease Expense (Income) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Estimated Useful Lives of Property and Equipment Property, Plant and Equipment [Table Text Block] Grant Revenue Revenue from Contract with Customer [Policy Text Block] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Information with regard to outstanding warrants to purchase common stock Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Estimated useful life Property, Plant and Equipment, Useful Life Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Balance (in shares) Balance (in shares) Shares, Outstanding Public offering Public Offering [Member] Public Offering [Member] CAPITAL STOCK AND WARRANTS Stockholders' Equity Note Disclosure [Text Block] Measurement Frequency [Domain] Measurement Frequency [Domain] Revenue: Revenues [Abstract] ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Product and Service [Domain] Product and Service [Domain] Software Computer Software, Intangible Asset [Member] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Deferred income tax provision Deferred Income Tax Expense (Benefit) Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Issuance of common stock for 401k match (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Accrued expenses Increase (Decrease) in Accrued Liabilities Michigan State University Michigan State University [Member] Michigan State University [Member] Concentration Risk [Table] Concentration Risk [Table] Sublease income Sublease Income 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Proceeds from warrants exercised Proceeds from Warrant Exercises Financial Instrument [Axis] Financial Instrument [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Document Period End Date Document Period End Date Short-term investments Short-Term Investments Total expenses Costs and Expenses Payables and Accruals [Abstract] Payables and Accruals [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Class of Stock [Line Items] Class of Stock [Line Items] Total lease liabilities Operating Lease, Liability Total assets Assets GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Stock-based Compensation Share-Based Payment Arrangement [Policy Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Charge for 401(k) company common stock match Charge for Company Common Stock Match The noncash charge representing the fair value of Company common stock issued by the company to participants in the Company's 401(k) plan as a matching contribution during the reporting period. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Change in foreign currency translation adjustment, net of income tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Accrued expenses Total accrued expenses Accrued Liabilities, Current Taxes paid on employees' behalf related to vesting of stock awards Payment Tax Withholding, Share Based Payment Arrangement, Excluding Employer Amount Payment Tax Withholding, Share Based Payment Arrangement, Excluding Employer Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated Cost Debt Securities, Available-for-Sale, Amortized Cost Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Number of shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Gross proceeds Sale of Stock, Consideration Received on Transaction Employee compensation and benefits Employee-related Liabilities, Current Accounts payable Accounts Payable, Current Stockholders’ Equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Loss from operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest BASIC AND DILUTED NET LOSS PER SHARE Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Warrants Warrant [Member] Entity Filer Category Entity Filer Category Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights U.S. UNITED STATES Weighted average remaining recognition period (years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Issuance of common stock for restricted units Stock Issued During Period, Value, Restricted Stock Award, Gross Commitments and contingencies (Note 9) Commitments and Contingencies Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Issuance of common stock in connection with stock offering, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding Preferred Stock, Value, Issued Letter of credit Letters of Credit Outstanding, Amount Options Employee And Directors Stock Options [Member] An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Revenue Revenue from Contract with Customer, Excluding Assessed Tax Collaborative agreement, term of option Collaborative Arrangement, Term Of Option For License Agreement Collaborative Arrangement, Term Of Option For License Agreement Issuance of common stock for warrant exercises (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Entity Address, City or Town Entity Address, City or Town Series A Warrants - expiration December 2022 Series A Warrant Expiring December 2022 [Member] Series A Warrant Expiring December 2022 [Member] Total number of common shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Cover [Abstract] Cover [Abstract] Right-of-Use Assets Lessee, Leases [Policy Text Block] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Principles of Consolidation Consolidation, Policy [Policy Text Block] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Unbilled receivables Increase (Decrease) in Contract with Customer, Asset Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Long-term lease liability Operating Lease Liability, Noncurrent, Excluding Lease Included on Balance Sheet Operating Lease Liability, Noncurrent, Excluding Lease Included on Balance Sheet Taxes paid on employees' behalf related to vesting of stock awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Other information as of: Lease, Other Information [Abstract] Lease, Other Information [Abstract] Canada CANADA Purchase of investments Payments to Acquire Short-Term Investments Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Equipment Equipment [Member] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Restricted cash Restricted Cash and Cash Equivalents Awarded (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Awards Restricted Stock Units (RSUs) [Member] CJ CheilJedang Corporation CJ CheilJedang Corporation [Member] CJ CheilJedang Corporation [Member] Current Fiscal Year End Date Current Fiscal Year End Date Series B Warrants - expiration May 2027 Series B Warrant Expiring May 2027 [Member] Series B Warrant Expiring May 2027 [Member] Collaborative agreement, quarterly research funding and option fees payable Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Amount of lease payments representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted net loss per share (in USD per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Issuance costs Payments of Stock Issuance Costs Accounts payable Increase (Decrease) in Accounts Payable Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance Schedule of Stock by Class [Table Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Number of additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Total current liabilities Liabilities, Current 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Exercise Price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Basic net loss per share (in USD per share) Earnings Per Share, Basic 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Intellectual Property Costs Intellectual Property Costs Policy [Text Block] Disclosure of accounting policy for intellectual property costs. Other income (expense): Nonoperating Income (Expense) [Abstract] Geographic Information Revenues from External Customers and Long-Lived Assets [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Maturity analysis of lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Collaborative agreement, term Collaborative Arrangement, Term Collaborative Arrangement, Term Entity Address, Address Line One Entity Address, Address Line One Schedule of Restricted Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Total stockholders’ equity Balance Balance Stockholders' Equity Attributable to Parent Product and Service [Axis] Product and Service [Axis] Unbilled receivables Unbilled Contracts Receivable Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Entity Interactive Data Current Entity Interactive Data Current Common stock issued in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Warrants - expiration September 2024 Warrant Expiring September 2024 [Member] Warrant Expiring September 2024 [Member] Change in unrealized loss on investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax U.S. government and agency securities US Government Corporations and Agencies Securities [Member] Accounts and unbilled receivables Accounts Receivable, After Allowance For Credit Loss, Current And Unbilled Contracts Receivable Accounts Receivable, After Allowance For Credit Loss, Current And Unbilled Contracts Receivable Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Schedule of accrued expenses Schedule of Accrued Liabilities [Table Text Block] Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Equity [Abstract] Equity [Abstract] Accumulated Deficit Retained Earnings [Member] Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Shares vested in period (in shares) Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Proceeds from the maturity of short-term investments Proceeds from Sale of Short-Term Investments Entity Tax Identification Number Entity Tax Identification Number Total lease cost, net Lease, Cost 19 Presidential Way Presidential Way, Woburn, Massachusetts [Member] Presidential Way, Woburn, Massachusetts [Member] Common Stock Common Stock [Member] Total other comprehensive income (loss) Effect of foreign currency translation and unrealized loss on investments Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Lease costs and other information Lease, Cost [Table Text Block] Number of shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Schedule of restricted stock units activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Statement [Table] Statement [Table] Unrestricted cash and cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Document Quarterly Report Document Quarterly Report Shares withheld for employee taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Furniture and fixtures Furniture and Fixtures [Member] Current Assets: Assets, Current [Abstract] Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Issuance of common stock for 401(k) match Stock Issued During Period, Value, Employee Benefit Plan Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Entity Central Index Key Entity Central Index Key Government securities US Treasury and Government [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity Components [Axis] Equity Components [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Research and Development Expense, Policy [Policy Text Block] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Proceeds from public offering, net of issuance costs Proceeds from Issuance of Private Placement Name of Property [Axis] Name of Property [Axis] Taxes paid on employees' behalf related to vesting of stock awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Collaborative agreement, research funding and option fees payable Collaborative Arrangement, Research Funding And Option Fees Payable Collaborative Arrangement, Research Funding And Option Fees Payable Options exercisable at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Segment Information Segment Reporting, Policy [Policy Text Block] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Other Other Accrued Liabilities, Current Document Fiscal Year Focus Document Fiscal Year Focus Entity [Domain] Entity [Domain] City Area Code City Area Code Professional services Accrued Professional Fees, Current Assets Assets [Abstract] Statement [Line Items] Statement [Line Items] General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Outstanding (in shares) Outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total other income (expense) Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] General and administrative Selling, General and Administrative Expense Additional shares authorized percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percent Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percent Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Unrealized (Loss) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Summary of option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Proceeds from warrants exercised Proceeds From Warrant Exercises, Net Proceeds From Warrant Exercises, Net Recent Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Field trials and related expenses Accrued Field Trials And Related Expenses, Current Accrued Field Trials And Related Expenses, Current Common stock, outstanding (in shares) Common Stock, Shares, Outstanding NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Customer [Domain] Customer [Domain] EX-101.PRE 9 yten-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - shares
 6 Months Ended
Jun. 30, 2022
Aug. 05, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-33133  
Entity Registrant Name YIELD10 BIOSCIENCE, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-3158289  
Entity Address, Address Line One 19 Presidential Way  
Entity Address, City or Town Woburn  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01801  
City Area Code 617  
Local Phone Number 583-1700  
Title of 12(b) Security Common Stock  
Trading Symbol YTEN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   4,914,121
Entity Central Index Key 0001121702  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
Revenue $ 103 $ 174 $ 252 $ 370
Expenses:        
Research and development 2,016 1,651 3,779 2,967
General and administrative 1,523 1,604 3,230 3,036
Total expenses 3,539 3,255 7,009 6,003
Loss from operations (3,436) (3,081) (6,757) (5,633)
Other income (expense):        
Other income (expense), net 2 0 1 (1)
Total other income (expense) 2 0 1 (1)
Loss from operations before income taxes (3,434) (3,081) (6,756) (5,634)
Income tax provision (9) (11) (18) (19)
Net loss $ (3,443) $ (3,092) $ (6,774) $ (5,653)
Basic net loss per share (in USD per share) $ (0.70) $ (0.64) $ (1.38) $ (1.23)
Diluted net loss per share (in USD per share) $ (0.70) $ (0.64) $ (1.38) $ (1.23)
Number of shares used in per share calculations:        
Basic (in shares) 4,900,298 4,868,156 4,894,638 4,583,723
Diluted (in shares) 4,900,298 4,868,156 4,894,638 4,583,723
Grant        
Revenue:        
Revenue $ 103 $ 174 $ 252 $ 370
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 3,180 $ 5,329
Short-term investments 6,978 10,661
Accounts receivable 35 164
Unbilled receivables 28 34
Prepaid expenses and other current assets 483 436
Total current assets 10,704 16,624
Restricted cash 264 264
Property and equipment, net 895 890
Right-of-use assets 2,162 2,354
Other assets 248 283
Total assets 14,273 20,415
Current Liabilities:    
Accounts payable 24 83
Accrued expenses 1,059 1,136
Current portion of lease liabilities 544 514
Total current liabilities 1,627 1,733
Lease liabilities, net of current portion 2,375 2,656
Total liabilities 4,002 4,389
Commitments and contingencies (Note 9)
Stockholders’ Equity:    
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding 0 0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at June 30, 2022 and December 31, 2021; 4,901,246 and 4,881,851 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively 49 49
Additional paid-in capital 403,347 402,283
Accumulated other comprehensive loss (220) (175)
Accumulated deficit (392,905) (386,131)
Total stockholders’ equity 10,271 16,026
Total liabilities and stockholders’ equity $ 14,273 $ 20,415
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value per share (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value per share (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 60,000,000 60,000,000
Common stock, issued (in shares) 4,901,246 4,881,851
Common stock, outstanding (in shares) 4,901,246 4,881,851
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net loss $ (3,443) $ (3,092) $ (6,774) $ (5,653)
Other comprehensive loss        
Change in unrealized loss on investments (1) 0 (22) 1
Change in foreign currency translation adjustment, net of income tax (26) 6 (23) 5
Total other comprehensive income (loss) (27) 6 (45) 6
Comprehensive loss $ (3,470) $ (3,086) $ (6,819) $ (5,647)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities    
Net loss $ (6,774) $ (5,653)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 128 108
Charge for 401(k) company common stock match 76 69
Stock-based compensation 1,011 739
Non-cash lease expense 192 175
Deferred income tax provision 19 14
Changes in operating assets and liabilities:    
Accounts receivable 129 10
Unbilled receivables 6 (11)
Prepaid expenses and other assets (37) 24
Accounts payable (59) 41
Accrued expenses (80) (69)
Lease liabilities (251) (223)
Net cash used in operating activities (5,640) (4,776)
Cash flows from investing activities    
Purchase of property and equipment (133) (136)
Purchase of investments (710) (3,891)
Proceeds from the maturity of short-term investments 4,371 5,250
Net cash provided by investing activities 3,528 1,223
Cash flows from financing activities    
Proceeds from warrants exercised 0 3,856
Proceeds from public offering, net of issuance costs 0 11,993
Taxes paid on employees' behalf related to vesting of stock awards (14) (83)
Net cash (used in) provided by financing activities (14) 15,766
Effect of exchange rate changes on cash, cash equivalents and restricted cash (23) 5
Net (decrease) increase in cash, cash equivalents and restricted cash (2,149) 12,218
Cash, cash equivalents and restricted cash at beginning of period 5,593 3,687
Cash, cash equivalents and restricted cash at end of period $ 3,444 $ 15,905
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance (in shares) at Dec. 31, 2020   3,334,048      
Balance at Dec. 31, 2020 $ 9,532 $ 33 $ 384,758 $ (159) $ (375,100)
Increase (decrease) in stockholders' equity          
Stock-based compensation expense 749   749    
Issuance of common stock for 401k match (in shares)   6,890      
Issuance of common stock for 401(k) match 62   62    
Issuance of common stock for restricted stock units (in shares)   5,555      
Issuance of common stock for restricted units 0   0    
Taxes paid on employees' behalf related to vesting of stock awards (83)   (83)    
Issuance of common stock for warrant exercises (in shares)   481,973      
Issuance of common stock for warrant exercises 3,856 $ 5 3,851    
Issuance of common stock in connection with stock offering, net of offering costs (in shares)   1,040,000      
Issuance of common stock in connection with stock offering, net of offering costs 11,993 $ 11 11,982    
Effect of foreign currency translation and unrealized loss on investments 6     6  
Net loss (5,653)       (5,653)
Balance (in shares) at Jun. 30, 2021   4,868,466      
Balance at Jun. 30, 2021 20,462 $ 49 401,319 (153) (380,753)
Balance (in shares) at Mar. 31, 2021   4,865,335      
Balance at Mar. 31, 2021 23,094 $ 49 400,865 (159) (377,661)
Increase (decrease) in stockholders' equity          
Stock-based compensation expense 414   414    
Issuance of common stock for 401k match (in shares)   3,131      
Issuance of common stock for 401(k) match 40   40    
Effect of foreign currency translation and unrealized loss on investments 6     6  
Net loss (3,092)       (3,092)
Balance (in shares) at Jun. 30, 2021   4,868,466      
Balance at Jun. 30, 2021 20,462 $ 49 401,319 (153) (380,753)
Balance (in shares) at Dec. 31, 2021   4,881,851      
Balance at Dec. 31, 2021 16,026 $ 49 402,283 (175) (386,131)
Increase (decrease) in stockholders' equity          
Stock-based compensation expense 1,012   1,012    
Issuance of common stock for 401k match (in shares)   12,917      
Issuance of common stock for 401(k) match 66   66    
Issuance of common stock for restricted stock units (in shares)   6,478      
Issuance of common stock for restricted units 0   0    
Taxes paid on employees' behalf related to vesting of stock awards (14)   (14)    
Effect of foreign currency translation and unrealized loss on investments (45)     (45)  
Net loss (6,774)       (6,774)
Balance (in shares) at Jun. 30, 2022   4,901,246      
Balance at Jun. 30, 2022 10,271 $ 49 403,347 (220) (392,905)
Balance (in shares) at Mar. 31, 2022   4,893,403      
Balance at Mar. 31, 2022 13,211 $ 49 402,817 (193) (389,462)
Increase (decrease) in stockholders' equity          
Stock-based compensation expense 489   489    
Issuance of common stock for 401k match (in shares)   7,843      
Issuance of common stock for 401(k) match 41   41    
Effect of foreign currency translation and unrealized loss on investments (27)     (27)  
Net loss (3,443)       (3,443)
Balance (in shares) at Jun. 30, 2022   4,901,246      
Balance at Jun. 30, 2022 $ 10,271 $ 49 $ 403,347 $ (220) $ (392,905)
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
ACCOUNTING POLICIES ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the FASB Accounting Standards Codification ("ASC"). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:
June 30,
2022		December 31,
2021
Cash and cash equivalents$3,180 $5,329 
Restricted cash264 264 
Total cash, cash equivalents and restricted cash$3,444 $5,593 
Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at June 30, 2022 and December 31, 2021 consists primarily of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.
Investments
The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments.
Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign Currency Translation
The functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Comprehensive Loss
Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.
The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as
well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.
At June 30, 2022, all of the Company's accounts and unbilled receivables of $63 were due from Michigan State University ("MSU") for support to a Department of Energy ("DOE") funded grant under which the Company serves as a subcontractor. The Company believes these receivables have a low risk of default. At December 31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support to the DOE grant.

Fair Value Measurements
The carrying amounts of the Company's financial instruments as of June 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 5 for further discussion on fair value measurements.
Segment Information
The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:
Asset DescriptionEstimated Useful Life (years)
Equipment3
Furniture and fixtures5
Software3
Leasehold improvementsShorter of useful life or term of lease
Lease Accounting
As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.
Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.
Grant Revenue
The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at June 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.
Research and Development
All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense.
General and Administrative Expenses
The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company.
Intellectual Property Costs
The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations.
Stock-Based Compensation
All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 7 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.
Recent Accounting Standards
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date.
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022.
The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same
effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION
    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address:
•petroleum replacement markets, in which the Company is developing Camelina oil for use as a biofuel feedstock and PHA Bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and
•food and nutrition markets, in which the Company is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets.
Yield10 also plans to license yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, Massachusetts, and has an Oilseed Center of Excellence located in Saskatoon, Saskatchewan, Canada. Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding.
    The accompanying condensed consolidated financial statements are presented in U.S. dollars, are unaudited, and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statement of the financial position as of June 30, 2022 and December 31, 2021, and for the results of operations for the interim periods ended June 30, 2022 and June 30, 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2022.
The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including the three and six months ended June 30, 2022.
    As of June 30, 2022, the Company held unrestricted cash, cash equivalents and investments of $10,158. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed consolidated financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on our current cash forecast, we have determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these condensed consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.
    If the Company issues equity or debt securities to raise additional funds in the future, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.
In February 2022, Russia initiated a military offensive in Ukraine which has resulted in significant uncertainty in the commodities market. The scope, intensity, duration and outcome of the ongoing war, resulting sanctions and resulting future market disruptions is uncertain and its continuation or escalation may have a material adverse effect on the Company. Ukraine, and the Black Sea region in general, are a major exporter of wheat and corn to the world, and the disruption of supply could cause volatility in prices and margins of these commodities and related products. Ukraine is also the largest supplier of sun seed and sun oil in the world which cannot be completely replaced from other geographic regions. The conflict in Ukraine has created disruptions in global supply chains and is expected to create dislocations of key agricultural commodities. While Yield10 has no direct business operations or assets within either Ukraine or Russia, the Company's plans and operating results could be adversely affected by a number of factors, including the crop growing decisions made by farmers in the U.S., Canada and South America as a consequence of supply shortages and rising commodity prices. These rising prices may negatively impact the Company's ability to contract suitable acreage for future crop trials or could delay its plans to commercialize Yield10's first Camelina plant varieties.
The Company’s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions and uncertainties. For instance, in July 2022, the U.S. Bureau of Labor Statistics reported that the Consumer Price Index for All Urban Consumers increased 9.1 percent, the largest 12-month increase since the 12-month period ending November 1981. If the inflation rate continues to increase, for example due to increases in the costs of labor and supplies, it will affect the Company's expenses and it might make it difficult for the Company to continue its research and development. Inflation could also adversely affect the ability of growers to enter into and fulfill their obligations under Camelina grain production agreements with the Company.
The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the evolving nature of the COVID-19 pandemic and the global responses to it, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for future periods.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2
BASIC AND DILUTED NET LOSS PER SHARE
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
BASIC AND DILUTED NET LOSS PER SHARE BASIC AND DILUTED NET LOSS PER SHARE
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards and warrants.
The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:
As of June 30,
 20222021
Options949,884 531,946 
Restricted Stock Awards54,250 18,862 
Warrants1,290,273 2,361,726 
Total2,294,407 2,912,534 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS INVESTMENTS
Investments consist of the following at June 30, 2022 and December 31, 2021:
Accumulated Cost at June 30, 2022UnrealizedMarket Value at June 30, 2022
Gain(Loss)
Short-term investments
     U.S. government and agency securities$7,008 $— $(30)$6,978 
          Total$7,008 $— $(30)$6,978 
Accumulated Cost at December 31, 2021UnrealizedMarket Value at December 31, 2021
Gain(Loss)
Short-term investments
     U.S. government and agency securities$10,669 $— $(8)$10,661 
          Total$10,669 $— $(8)$10,661 
All investments are classified as available for sale as of June 30, 2022 and December 31, 2021.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.
The Company’s financial assets classified as Level 2 at June 30, 2022 and December 31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of June 30, 2022 and December 31, 2021.
The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.
Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets		Significant other
observable inputs		Significant
unobservable  inputs		Balance as of
Description(Level 1)(Level 2)(Level 3)June 30, 2022
Cash equivalents:
Money market funds
$2,061 $— $— $2,061 
Short-term investments:
U.S. government and agency securities
— 6,978 — 6,978 
Total assets$2,061 $6,978 $— $9,039 

Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets		Significant other
observable inputs		Significant
unobservable  inputs		Balance as of
Description(Level 1)(Level 2)(Level 3)December 31, 2021
Cash equivalents:
Money market funds
$4,878 $— $— $4,878 
Short-term investments:
U.S. government and agency securities
— 10,661 — 10,661 
Total assets$4,878 $10,661 $— $15,539 
There were no transfers of financial assets between category levels during the three and six months ended June 30, 2022 and the three and six months ended June 30, 2021.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2
ACCRUED EXPENSES
 6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES ACCRUED EXPENSES
Accrued expenses consisted of the following at:
June 30,
2022		December 31,
2021
Employee compensation and benefits$381 $452 
Leased facilities61 71 
Professional services267 264 
Field trials and related expenses215 97 
Other135 252 
Total accrued expenses$1,059 $1,136 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Expense Information for Employee and Non-Employee Stock Awards
The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors of $488 and $1,011 for the three and six months ended June 30, 2022 and $415 and $739 for the three and six months ended June 30, 2021. At June 30, 2022, there was approximately $4,009 of unvested awards not yet recognized as compensation expense.
The compensation expense related to unvested stock awards is expected to be recognized over a remaining weighted average period of 2.80 years.
Stock Options
A summary of option activity for the six months ended June 30, 2022 is as follows:
Number of
Shares		Weighted Average
Exercise Price
Outstanding at December 31, 2021722,765 $19.22 
Granted227,224 $3.85 
Expired(105)$5,849.14 
Outstanding at June 30, 2022949,884 $14.90 
Options exercisable at June 30, 2022318,699 $30.12 
In accordance with the terms of the Company's 2018 Stock Option and Incentive Plan ("2018 Stock Plan"), effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of 244,092 shares and 166,702 shares, respectively, to the 2018 Stock Plan, which represented 5% of the Company's outstanding common stock on the day prior to each increase. At its annual meeting of stockholders on May 24, 2021, stockholders approved an amendment to the 2018 Stock Plan to add 300,000 more shares to the plan. As of June 30, 2022, 29,964 shares remain available to be awarded from the 2018 Stock Plan.
Restricted Stock Units
The Company records stock compensation expense for restricted stock units ("RSUs") on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date fair market value. As RSUs vest, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount from the common stock issuable at the vest date. During the six months ended June 30, 2022, 9,430 employee RSUs vested, of which 2,952 common shares with a total market value of $13 were withheld to pay employee tax withholding.
A summary of RSU activity for the six months ended June 30, 2022 is as follows:
Number of RSUsWeighted Average Remaining Contractual Life (years)
Outstanding at December 31, 20219,430 
Awarded54,250 
Released(9,430)
Outstanding at June 30, 202254,250 0.36
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES
 6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
LEASES LEASES
Maturity Analysis of Lease Liabilities
The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At June 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows:
Year ended December 31,Undiscounted Cash Flows
2022 (July to December)$367 
2023749 
2024771 
2025793 
2026747 
Total undiscounted future lease payments3,427 
Amount of lease payments representing interest(512)
Total lease liabilities$2,915 
     Short-term lease liability$544 
     Long-term lease liability$2,371 
Quantitative Disclosure of Lease Costs
Three Months Ended
   June 30,		Six Months Ended
  June 30,
2022202120222021
Lease cost:
Operating lease cost$151 $151 $303 $303 
Short-term lease cost183 169 332 326 
Sublease income(153)(146)(295)(320)
Total lease cost, net$181 $174 $340 $309 
Other information as of:June 30, 2022December 31, 2021
Weighted-average remaining lease term (years)4.44.9
Weighted-average discount rate7.25%7.25%
Real Estate Leases
    During 2016, the Company entered into a lease agreement, as amended, for its headquarters pursuant to which the Company leases 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease agreement will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and
operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for certain tenant improvements that resulted in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229.
In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The CJ sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,427 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.
The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 7,800 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. YOI's leases for these facilities expire on various dates through May 2023.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Contractual Commitments    
Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")
In November 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. The Company is paying Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $63 remains outstanding as of June 30, 2022. As part of the agreement, the Company has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. The current agreement terminates automatically on its second anniversary unless terminated earlier in accordance with the terms of the agreement.
License Agreement with the University of Missouri ("UM")
Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops. Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production. The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops.
Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone.
The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products. The Company or UM may terminate the license agreement in accordance with the terms of the agreement.
Facility Leases
The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026. See Note 8.
Litigation
From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.
Guarantees
    As of June 30, 2022 and December 31, 2021, the Company did not have significant liabilities recorded for guarantees.
The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of June 30, 2022 and December 31, 2021.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2
GEOGRAPHIC INFORMATION
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
GEOGRAPHIC INFORMATION GEOGRAPHIC INFORMATION
The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled.
U.S.CanadaTotal
Three Months Ended June 30, 2022
Revenue$103 $— $103 
Three Months Ended June 30, 2021
Revenue$174 $— $174 
Six Months Ended June 30, 2022
Revenue$252 $— $252 
Six Months Ended June 30, 2021
Revenue$331 $39 $370 
Identifiable long-lived assets
June 30, 2022$752 $143 $895 
June 30, 2021$896 $53 $949 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2
CAPITAL STOCK AND WARRANTS
 6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
CAPITAL STOCK AND WARRANTS CAPITAL STOCK AND WARRANTS
Common Stock
Registered Public Offerings
    On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747.
Preferred Stock
The Company's Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of $0.01 par value preferred stock.
Warrants
The following table summarizes information regarding outstanding warrants to purchase common stock as of June 30, 2022:
IssuanceNumber of Shares Issuable Upon Exercise of Outstanding WarrantsExercise Price Per Share of Common StockExpiration Date
November 2019 Public Offering - Series B395,528 $8.00 May 19, 2027
November 2019 Private Placement - Series B718,750 $8.00 May 19, 2027
December 2017 Public Offering - Series A160,975 $90.00 December 21, 2022
July 2017 Registered Direct Offering14,270 $201.60 January 7, 2024
Consultant750 $116.00 September 11, 2024
Total1,290,273 
Effective May 19, 2022, 1,071,453 Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued. During the six months ended June 30, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing $3,856 in cash proceeds. During the six months ended June 30, 2022, no warrants were exercised by warrant holders.
Reserved Shares
The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:
June 30,
2022		December 31,
2021
Stock Options949,884 722,765 
RSUs54,250 9,430 
Warrants1,290,273 2,361,726 
Total number of common shares reserved for future issuance2,294,407 3,093,921 
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").
Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp.
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.
Investments
Investments
The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments.
Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign Currency Translation Foreign Currency TranslationThe functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Comprehensive Income (Loss)
Comprehensive Loss
Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.
Income Taxes
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.
The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as
well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.
Fair Value Measurements Fair Value MeasurementsThe carrying amounts of the Company's financial instruments as of June 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments.
Segment Information
Segment Information
The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:
Asset DescriptionEstimated Useful Life (years)
Equipment3
Furniture and fixtures5
Software3
Leasehold improvementsShorter of useful life or term of lease
Right-of-Use Assets
Lease Accounting
As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.
Grant Revenue
Grant Revenue
The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at June 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.
Research and Development
Research and Development
All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense.
General and Administrative Expenses
General and Administrative Expenses
The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company.
Intellectual Property Costs
Intellectual Property Costs
The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations.
Stock-based Compensation Stock-Based CompensationAll share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award.
Recent Accounting Standards
Recent Accounting Standards
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date.
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022.
The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same
effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Schedule of Restricted Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:
June 30,
2022		December 31,
2021
Cash and cash equivalents$3,180 $5,329 
Restricted cash264 264 
Total cash, cash equivalents and restricted cash$3,444 $5,593 
Schedule of Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:
June 30,
2022		December 31,
2021
Cash and cash equivalents$3,180 $5,329 
Restricted cash264 264 
Total cash, cash equivalents and restricted cash$3,444 $5,593 
Estimated Useful Lives of Property and Equipment Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:
Asset DescriptionEstimated Useful Life (years)
Equipment3
Furniture and fixtures5
Software3
Leasehold improvementsShorter of useful life or term of lease
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2
BASIC AND DILUTED NET LOSS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares
The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:
As of June 30,
 20222021
Options949,884 531,946 
Restricted Stock Awards54,250 18,862 
Warrants1,290,273 2,361,726 
Total2,294,407 2,912,534 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS (Tables)
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of investment holdings
Investments consist of the following at June 30, 2022 and December 31, 2021:
Accumulated Cost at June 30, 2022UnrealizedMarket Value at June 30, 2022
Gain(Loss)
Short-term investments
     U.S. government and agency securities$7,008 $— $(30)$6,978 
          Total$7,008 $— $(30)$6,978 
Accumulated Cost at December 31, 2021UnrealizedMarket Value at December 31, 2021
Gain(Loss)
Short-term investments
     U.S. government and agency securities$10,669 $— $(8)$10,661 
          Total$10,669 $— $(8)$10,661 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Assets and liabilities measured at fair value on a recurring basis
The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.
Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets		Significant other
observable inputs		Significant
unobservable  inputs		Balance as of
Description(Level 1)(Level 2)(Level 3)June 30, 2022
Cash equivalents:
Money market funds
$2,061 $— $— $2,061 
Short-term investments:
U.S. government and agency securities
— 6,978 — 6,978 
Total assets$2,061 $6,978 $— $9,039 

Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets		Significant other
observable inputs		Significant
unobservable  inputs		Balance as of
Description(Level 1)(Level 2)(Level 3)December 31, 2021
Cash equivalents:
Money market funds
$4,878 $— $— $4,878 
Short-term investments:
U.S. government and agency securities
— 10,661 — 10,661 
Total assets$4,878 $10,661 $— $15,539 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2
ACCRUED EXPENSES (Tables)
 6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Schedule of accrued expenses
Accrued expenses consisted of the following at:
June 30,
2022		December 31,
2021
Employee compensation and benefits$381 $452 
Leased facilities61 71 
Professional services267 264 
Field trials and related expenses215 97 
Other135 252 
Total accrued expenses$1,059 $1,136 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of option activity
A summary of option activity for the six months ended June 30, 2022 is as follows:
Number of
Shares		Weighted Average
Exercise Price
Outstanding at December 31, 2021722,765 $19.22 
Granted227,224 $3.85 
Expired(105)$5,849.14 
Outstanding at June 30, 2022949,884 $14.90 
Options exercisable at June 30, 2022318,699 $30.12 
Schedule of restricted stock units activity
A summary of RSU activity for the six months ended June 30, 2022 is as follows:
Number of RSUsWeighted Average Remaining Contractual Life (years)
Outstanding at December 31, 20219,430 
Awarded54,250 
Released(9,430)
Outstanding at June 30, 202254,250 0.36
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES (Tables)
 6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Maturity analysis of lease liabilities At June 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows:
Year ended December 31,Undiscounted Cash Flows
2022 (July to December)$367 
2023749 
2024771 
2025793 
2026747 
Total undiscounted future lease payments3,427 
Amount of lease payments representing interest(512)
Total lease liabilities$2,915 
     Short-term lease liability$544 
     Long-term lease liability$2,371 
Lease costs and other information
Three Months Ended
   June 30,		Six Months Ended
  June 30,
2022202120222021
Lease cost:
Operating lease cost$151 $151 $303 $303 
Short-term lease cost183 169 332 326 
Sublease income(153)(146)(295)(320)
Total lease cost, net$181 $174 $340 $309 
Other information as of:June 30, 2022December 31, 2021
Weighted-average remaining lease term (years)4.44.9
Weighted-average discount rate7.25%7.25%
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2
GEOGRAPHIC INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Schedule of the geographic distribution of revenues and long-lived assets
The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled.
U.S.CanadaTotal
Three Months Ended June 30, 2022
Revenue$103 $— $103 
Three Months Ended June 30, 2021
Revenue$174 $— $174 
Six Months Ended June 30, 2022
Revenue$252 $— $252 
Six Months Ended June 30, 2021
Revenue$331 $39 $370 
Identifiable long-lived assets
June 30, 2022$752 $143 $895 
June 30, 2021$896 $53 $949 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2
CAPITAL STOCK AND WARRANTS (Tables)
 6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Information with regard to outstanding warrants to purchase common stock The following table summarizes information regarding outstanding warrants to purchase common stock as of June 30, 2022:
IssuanceNumber of Shares Issuable Upon Exercise of Outstanding WarrantsExercise Price Per Share of Common StockExpiration Date
November 2019 Public Offering - Series B395,528 $8.00 May 19, 2027
November 2019 Private Placement - Series B718,750 $8.00 May 19, 2027
December 2017 Public Offering - Series A160,975 $90.00 December 21, 2022
July 2017 Registered Direct Offering14,270 $201.60 January 7, 2024
Consultant750 $116.00 September 11, 2024
Total1,290,273 
Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance
The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:
June 30,
2022		December 31,
2021
Stock Options949,884 722,765 
RSUs54,250 9,430 
Warrants1,290,273 2,361,726 
Total number of common shares reserved for future issuance2,294,407 3,093,921 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTING POLICIES - Additional Information (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Concentration of credit risk    
Restricted cash $ 264 $ 264
Number of operating segments | segment 1  
Michigan State University    
Concentration of credit risk    
Accounts and unbilled receivables $ 63 $ 198
Equipment    
Concentration of credit risk    
Estimated useful life 3 years  
Furniture and fixtures    
Concentration of credit risk    
Estimated useful life 5 years  
Software    
Concentration of credit risk    
Estimated useful life 3 years  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2
ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]        
Cash and cash equivalents $ 3,180 $ 5,329    
Restricted cash 264 264    
Total cash, cash equivalents and restricted cash $ 3,444 $ 5,593 $ 15,905 $ 3,687
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)
$ in Thousands
Jun. 30, 2022
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Unrestricted cash and cash equivalents and short-term investments $ 10,158
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2
BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares
 3 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Antidilutive securities    
Antidilutive common stock excluded from the calculation of dilutive shares 2,294,407 2,912,534
Options    
Antidilutive securities    
Antidilutive common stock excluded from the calculation of dilutive shares 949,884 531,946
Restricted Stock Awards    
Antidilutive securities    
Antidilutive common stock excluded from the calculation of dilutive shares 54,250 18,862
Warrants    
Antidilutive securities    
Antidilutive common stock excluded from the calculation of dilutive shares 1,290,273 2,361,726
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Accumulated Cost   $ 10,669
Unrealized Gain   0
Unrealized (Loss)   (8)
Market Value   10,661
Government securities    
Debt Securities, Available-for-sale [Line Items]    
Accumulated Cost $ 7,008 10,669
Unrealized Gain 0 0
Unrealized (Loss) (30) (8)
Market Value $ 6,978 $ 10,661
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments   $ 10,661
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets $ 9,039 15,539
Fair Value, Measurements, Recurring | U.S. government and agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 6,978 10,661
Fair Value, Measurements, Recurring | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 2,061 4,878
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 2,061 4,878
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets (Level 1) | U.S. government and agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 0 0
Fair Value, Measurements, Recurring | Quoted prices in active markets for identical assets (Level 1) | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 2,061 4,878
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 6,978 10,661
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | U.S. government and agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 6,978 10,661
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 0 0
Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | U.S. government and agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 0 0
Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 0 $ 0
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Employee compensation and benefits $ 381 $ 452
Leased facilities 61 71
Professional services 267 264
Field trials and related expenses 215 97
Other 135 252
Total accrued expenses $ 1,059 $ 1,136
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jan. 01, 2022
May 24, 2021
Jan. 01, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Stock-based compensation              
Stock-based compensation       $ (488) $ 415 $ 1,011 $ 739
Weighted Average Exercise Price              
Number of additional shares authorized 244,092 300,000 166,702        
Additional shares authorized percentage 5.00%            
Number of shares available for grant       29,964   29,964  
Shares withheld for employee taxes (in shares)           2,952  
Taxes paid on employees' behalf related to vesting of stock awards           $ 13  
Employee stock option              
Stock-based compensation              
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized       $ 4,009   $ 4,009  
Weighted average remaining recognition period (years)           2 years 9 months 18 days  
Options              
Number of Shares              
Outstanding at the beginning of the period (in shares) 722,765         722,765  
Granted (in shares)           227,224  
Expired (in shares)           (105)  
Outstanding at the end of the period (in shares)       949,884   949,884  
Options exercisable at the end of the period (in shares)       318,699   318,699  
Weighted Average Exercise Price              
Outstanding at the beginning of the period (in dollars per share) $ 19.22         $ 19.22  
Granted (in dollars per share)           3.85  
Expired (in dollars per share)           5,849.14  
Outstanding at the end of the period (in dollars per share)       $ 14.90   14.90  
Options exercisable at the end of the period (in dollars per share)       $ 30.12   $ 30.12  
Restricted Stock Awards              
Weighted Average Exercise Price              
Shares vested in period (in shares)           9,430  
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION - RSU Activity (Details) - Restricted Stock Awards
 6 Months Ended
Jun. 30, 2022
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding (in shares) 9,430
Awarded (in shares) 54,250
Released (in shares) (9,430)
Outstanding (in shares) 54,250
Weighted average remaining contractual life 4 months 9 days
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES - Narrative (Details)
$ in Thousands
 1 Months Ended
Oct. 31, 2016
USD ($)
ft²
Jun. 30, 2022
USD ($)
ft²
Feb. 29, 2020
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Leased area (in sq ft) | ft²   22,213  
Undiscounted future lease payments | $   $ 3,427  
19 Presidential Way      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Letter of credit | $     $ 229
Subleased area (in sq ft) | ft² 9,874    
410 Downey Road and 110 Gymnasium Place      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Leased area (in sq ft) | ft²   7,800  
CJ CheilJedang Corporation | 19 Presidential Way      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Letter of credit | $ $ 103    
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES - Maturity Analysis of Lease Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Leases [Abstract]    
2022 (July to December) $ 367  
2021 749  
2022 771  
2023 793  
2024 747  
Total undiscounted future lease payments 3,427  
Amount of lease payments representing interest (512)  
Total lease liabilities 2,915  
Short-term lease liability 544 $ 514
Long-term lease liability $ 2,371  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES - Quantitative Disclosure of Lease Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Lease cost:          
Operating lease cost $ 151 $ 151 $ 303 $ 303  
Short-term lease cost 183 169 332 326  
Sublease income (153) (146) (295) (320)  
Total lease cost, net $ 181 $ 174 $ 340 $ 309  
Other information as of:          
Weighted-average remaining lease term 4 years 4 months 24 days   4 years 4 months 24 days   4 years 10 months 24 days
Weighted-average discount rate 7.25%   7.25%   7.25%
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 1 Months Ended
Nov. 12, 2020
Nov. 30, 2020
Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative agreement, term   2 years  
Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative agreement, quarterly research funding and option fees payable   $ 31  
Collaborative agreement, research funding and option fees payable   $ 250 $ 63
Collaborative agreement, term of option 2 years    
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2
GEOGRAPHIC INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Geographic Information          
Revenue $ 103 $ 174 $ 252 $ 370  
Identifiable long-lived assets 895 949 895 949 $ 890
U.S.          
Geographic Information          
Revenue 103 174 252 331  
Identifiable long-lived assets 752 896 752 896  
Canada          
Geographic Information          
Revenue 0 0 0 39  
Identifiable long-lived assets $ 143 $ 53 $ 143 $ 53  
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2
CAPITAL STOCK AND WARRANTS - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
May 19, 2022
Feb. 03, 2021
Jun. 30, 2021
Jun. 30, 2022
Dec. 31, 2021
Class of Stock [Line Items]          
Preferred stock, authorized (in shares)       5,000,000 5,000,000
Preferred stock, par value per share (in dollars per share)       $ 0.01 $ 0.01
Warrants expired (in shares) 1,071,453        
Proceeds from warrants exercised     $ 3,856    
Common Stock          
Class of Stock [Line Items]          
Warrants exercised (in shares)     481,973    
Public offering          
Class of Stock [Line Items]          
Common stock issued in offering (in shares)   1,040,000      
Common stock price (in dollars per share)   $ 12.25      
Gross proceeds   $ 12,740      
Issuance costs   $ 747      
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2
CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details)
Jun. 30, 2022
$ / shares
shares
Class of Stock [Line Items]  
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) 1,290,273
Warrants - expiration January 2024  
Class of Stock [Line Items]  
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) 14,270
Exercise Price (in dollars per share) | $ / shares $ 201.60
Warrants - expiration September 2024  
Class of Stock [Line Items]  
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) 750
Exercise Price (in dollars per share) | $ / shares $ 116.00
Public offering | Series B Warrants - expiration May 2027  
Class of Stock [Line Items]  
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) 395,528
Exercise Price (in dollars per share) | $ / shares $ 8.00
Public offering | Series A Warrants - expiration December 2022  
Class of Stock [Line Items]  
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) 160,975
Exercise Price (in dollars per share) | $ / shares $ 90.00
Private offering | Series B Warrants - expiration May 2027  
Class of Stock [Line Items]  
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) 718,750
Exercise Price (in dollars per share) | $ / shares $ 8.00
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.2
CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details) - shares
Jun. 30, 2022
Dec. 31, 2021
Class of Stock [Line Items]    
Total number of common shares reserved for future issuance 2,294,407 3,093,921
Options    
Class of Stock [Line Items]    
Total number of common shares reserved for future issuance 949,884 722,765
Restricted Stock Awards    
Class of Stock [Line Items]    
Total number of common shares reserved for future issuance 54,250 9,430
Warrants    
Class of Stock [Line Items]    
Total number of common shares reserved for future issuance 1,290,273 2,361,726
XML 55 yten-20220630_htm.xml IDEA: XBRL DOCUMENT 0001121702 2022-01-01 2022-06-30 0001121702 2022-08-05 0001121702 2022-06-30 0001121702 2021-12-31 0001121702 us-gaap:GrantMember 2022-04-01 2022-06-30 0001121702 us-gaap:GrantMember 2021-04-01 2021-06-30 0001121702 us-gaap:GrantMember 2022-01-01 2022-06-30 0001121702 us-gaap:GrantMember 2021-01-01 2021-06-30 0001121702 2022-04-01 2022-06-30 0001121702 2021-04-01 2021-06-30 0001121702 2021-01-01 2021-06-30 0001121702 2020-12-31 0001121702 2021-06-30 0001121702 us-gaap:CommonStockMember 2022-03-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001121702 us-gaap:RetainedEarningsMember 2022-03-31 0001121702 2022-03-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001121702 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001121702 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001121702 us-gaap:CommonStockMember 2022-06-30 0001121702 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001121702 us-gaap:RetainedEarningsMember 2022-06-30 0001121702 us-gaap:CommonStockMember 2021-03-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001121702 us-gaap:RetainedEarningsMember 2021-03-31 0001121702 2021-03-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001121702 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001121702 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001121702 us-gaap:CommonStockMember 2021-06-30 0001121702 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001121702 us-gaap:RetainedEarningsMember 2021-06-30 0001121702 us-gaap:CommonStockMember 2021-12-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001121702 us-gaap:RetainedEarningsMember 2021-12-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001121702 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001121702 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001121702 us-gaap:CommonStockMember 2020-12-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001121702 us-gaap:RetainedEarningsMember 2020-12-31 0001121702 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001121702 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001121702 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001121702 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001121702 yten:MichiganStateUniversityMember 2022-06-30 0001121702 yten:MichiganStateUniversityMember 2021-12-31 0001121702 us-gaap:EquipmentMember 2022-01-01 2022-06-30 0001121702 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-06-30 0001121702 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-01 2022-06-30 0001121702 yten:EmployeeAndDirectorsStockOptionsMember 2022-04-01 2022-06-30 0001121702 yten:EmployeeAndDirectorsStockOptionsMember 2021-04-01 2021-06-30 0001121702 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001121702 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001121702 us-gaap:WarrantMember 2022-04-01 2022-06-30 0001121702 us-gaap:WarrantMember 2021-04-01 2021-06-30 0001121702 us-gaap:USTreasuryAndGovernmentMember 2022-06-30 0001121702 us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-06-30 0001121702 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-06-30 0001121702 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-06-30 0001121702 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-06-30 0001121702 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-12-31 0001121702 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-12-31 0001121702 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-12-31 0001121702 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-12-31 0001121702 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001121702 us-gaap:EmployeeStockOptionMember 2022-06-30 0001121702 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001121702 yten:EmployeeAndDirectorsStockOptionsMember 2021-12-31 0001121702 yten:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-06-30 0001121702 yten:EmployeeAndDirectorsStockOptionsMember 2022-06-30 0001121702 2022-01-01 2022-01-01 0001121702 2021-01-01 2021-01-01 0001121702 2021-05-24 2021-05-24 0001121702 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001121702 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001121702 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001121702 yten:PresidentialWayWoburnMassachusettsMember 2020-02-29 0001121702 yten:PresidentialWayWoburnMassachusettsMember 2016-10-01 2016-10-31 0001121702 yten:PresidentialWayWoburnMassachusettsMember yten:CJCheilJedangCorporationMember 2016-10-31 0001121702 yten:A410DowneyRoadAnd110GymnasiumPlaceMember 2022-06-30 0001121702 us-gaap:CollaborativeArrangementMember 2020-11-30 0001121702 2020-11-01 2020-11-30 0001121702 us-gaap:CollaborativeArrangementMember 2022-06-30 0001121702 us-gaap:CollaborativeArrangementMember 2020-11-12 2020-11-12 0001121702 country:US 2022-04-01 2022-06-30 0001121702 country:CA 2022-04-01 2022-06-30 0001121702 country:US 2021-04-01 2021-06-30 0001121702 country:CA 2021-04-01 2021-06-30 0001121702 country:US 2022-01-01 2022-06-30 0001121702 country:CA 2022-01-01 2022-06-30 0001121702 country:US 2021-01-01 2021-06-30 0001121702 country:CA 2021-01-01 2021-06-30 0001121702 country:US 2022-06-30 0001121702 country:CA 2022-06-30 0001121702 country:US 2021-06-30 0001121702 country:CA 2021-06-30 0001121702 yten:PublicOfferingMember 2021-02-03 2021-02-03 0001121702 yten:PublicOfferingMember 2021-02-03 0001121702 yten:SeriesBWarrantExpiringMay2027Member yten:PublicOfferingMember 2022-06-30 0001121702 yten:SeriesBWarrantExpiringMay2027Member us-gaap:PrivatePlacementMember 2022-06-30 0001121702 yten:SeriesAWarrantExpiringDecember2022Member yten:PublicOfferingMember 2022-06-30 0001121702 yten:WarrantExpiringJanuary2024Member 2022-06-30 0001121702 yten:WarrantExpiringSeptember2024Member 2022-06-30 0001121702 2022-05-19 2022-05-19 0001121702 us-gaap:EmployeeStockOptionMember 2021-12-31 0001121702 us-gaap:WarrantMember 2022-06-30 0001121702 us-gaap:WarrantMember 2021-12-31 shares iso4217:USD iso4217:USD shares yten:segment pure utr:sqft 0001121702 --12-31 2022 Q2 false 10-Q true 2022-06-30 false 001-33133 YIELD10 BIOSCIENCE, INC. DE 04-3158289 19 Presidential Way Woburn MA 01801 617 583-1700 Common Stock YTEN NASDAQ Yes Yes Non-accelerated Filer true false false 4914121 3180000 5329000 6978000 10661000 35000 164000 28000 34000 483000 436000 10704000 16624000 264000 264000 895000 890000 2162000 2354000 248000 283000 14273000 20415000 24000 83000 1059000 1136000 544000 514000 1627000 1733000 2375000 2656000 4002000 4389000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.01 0.01 60000000 60000000 4901246 4901246 4881851 4881851 49000 49000 403347000 402283000 -220000 -175000 -392905000 -386131000 10271000 16026000 14273000 20415000 103000 174000 252000 370000 103000 174000 252000 370000 2016000 1651000 3779000 2967000 1523000 1604000 3230000 3036000 3539000 3255000 7009000 6003000 -3436000 -3081000 -6757000 -5633000 2000 0 1000 -1000 2000 0 1000 -1000 -3434000 -3081000 -6756000 -5634000 9000 11000 18000 19000 -3443000 -3092000 -6774000 -5653000 -5653000 -0.70 -0.70 -0.64 -0.64 -1.38 -1.38 -1.23 -1.23 4900298 4900298 4868156 4868156 4894638 4894638 4583723 4583723 -3443000 -3092000 -6774000 -5653000 -5653000 -1000 0 -22000 1000 -26000 6000 -23000 5000 -27000 6000 -45000 6000 -3470000 -3086000 -6819000 -5647000 -6774000 -5653000 -5653000 128000 108000 76000 69000 1011000 739000 192000 175000 19000 14000 -129000 -10000 -6000 11000 37000 -24000 -59000 41000 -80000 -69000 -251000 -223000 -5640000 -5640000 -4776000 -4776000 133000 136000 710000 3891000 4371000 5250000 3528000 3528000 1223000 1223000 0 3856000 0 11993000 14000 83000 -14000 -14000 15766000 15766000 -23000 5000 -2149000 12218000 5593000 3687000 3444000 15905000 4893403 49000 402817000 -193000 -389462000 13211000 489000 489000 7843 41000 41000 -27000 -27000 -3443000 -3443000 4901246 49000 403347000 -220000 -392905000 10271000 4865335 49000 400865000 -159000 -377661000 23094000 414000 414000 3131 40000 40000 6000 6000 -3092000 -3092000 4868466 49000 401319000 -153000 -380753000 20462000 4881851 49000 402283000 -175000 -386131000 16026000 1012000 1012000 12917 66000 66000 6478 0 0 14000 14000 -45000 -45000 -6774000 -6774000 4901246 49000 403347000 -220000 -392905000 10271000 3334048 33000 384758000 -159000 -375100000 9532000 749000 749000 6890 62000 62000 481973 5000 3851000 3856000 5555 0 0 83000 83000 1040000 11000 11982000 11993000 6000 6000 -5653000 -5653000 4868466 49000 401319000 -153000 -380753000 20462000 NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address:</span></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">petroleum replacement markets, in which the Company is developing Camelina oil for use as a biofuel feedstock and PHA Bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and </span></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">food and nutrition markets, in which the Company is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 also plans to license yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, Massachusetts, and has an Oilseed Center of Excellence located in Saskatoon, Saskatchewan, Canada. Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The accompanying condensed consolidated financial statements are presented in U.S. dollars, are unaudited, and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statement of the financial position as of June 30, 2022 and December 31, 2021, and for the results of operations for the interim periods ended June 30, 2022 and June 30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021, which are contained in the Company’s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1121702/000112170222000008/yten-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form 10-K</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> filed with the SEC on March 25, 2022.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of June 30, 2022, the Company held unrestricted cash, cash equivalents and investments of $10,158. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements-Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed consolidated financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on our current cash forecast, we have determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these condensed consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    If the Company issues equity or debt securities to raise additional funds in the future, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia initiated a military offensive in Ukraine which has resulted in significant uncertainty in the commodities market. The scope, intensity, duration and outcome of the ongoing war, resulting sanctions and resulting future market disruptions is uncertain and its continuation or escalation may have a material adverse effect on the Company. Ukraine, and the Black Sea region in general, are a major exporter of wheat and corn to the world, and the disruption of supply could cause volatility in prices and margins of these commodities and related products. Ukraine is also the largest supplier of sun seed and sun oil in the world which cannot be completely replaced from other geographic regions. The conflict in Ukraine has created disruptions in global supply chains and is expected to create dislocations of key agricultural commodities. While Yield10 has no direct business operations or assets within either Ukraine or Russia, the Company's plans and operating results could be adversely affected by a number of factors, including the crop growing decisions made by farmers in the U.S., Canada and South America as a consequence of supply shortages and rising commodity prices. These rising prices may negatively impact the Company's ability to contract suitable acreage for future crop trials or could delay its plans to commercialize Yield10's first Camelina plant varieties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions and uncertainties. For instance, in July 2022, the U.S. Bureau of Labor Statistics reported that the Consumer Price Index for All Urban Consumers increased 9.1 percent, the largest 12-month increase since the 12-month period ending November 1981. If the inflation rate continues to increase, for example due to increases in the costs of labor and supplies, it will affect the Company's expenses and it might make it difficult for the Company to continue its research and development. Inflation could also adversely affect the ability of growers to enter into and fulfill their obligations under Camelina grain production agreements with the Company.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the evolving nature of the COVID-19 pandemic and the global responses to it, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for future periods.</span></div> 10158000 ACCOUNTING POLICIES<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the FASB Accounting Standards Codification ("ASC"). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:</span></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at June 30, 2022 and December 31, 2021 consists primarily of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;padding-right:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2022, all of the Company's accounts and unbilled receivables of $63 were due from Michigan State University ("MSU") for support to a Department of Energy ("DOE") funded grant under which the Company serves as a subcontractor. The Company believes these receivables have a low risk of default. At December 31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support to the DOE grant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's financial instruments as of June 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 5 for further discussion on fair value measurements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at June 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 7 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future.</span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently issued amendments to ASU 2016-13, which have the same </span></div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance is effective for fiscal years beginning after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements.</span> The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, including accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets GAAP that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the unaudited condensed consolidated financial statements are to the FASB Accounting Standards Codification ("ASC"). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, YOI and Yield10 Bioscience Securities Corp. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.</span></div> The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's unaudited condensed consolidated balance sheets included herein:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3180000 5329000 264000 264000 3444000 5593000 264000 264000 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-than-temporary impairments of equity investments are recognized in the Company's unaudited condensed consolidated statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div> Foreign Currency TranslationThe functional currency for YOI is the Canadian dollar. Foreign denominated assets and liabilities of YOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the unaudited condensed consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its unaudited condensed consolidated statement of operations during the fiscal period when the dissolution or sale occurs. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the unaudited condensed consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as </span></div>well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.</span></div> 63000 198000 Fair Value MeasurementsThe carrying amounts of the Company's financial instruments as of June 30, 2022 and December 31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.</span></div> 1 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table></div> Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table> P3Y P5Y P3Y <div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.</span></div> <div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at June 30, 2022 and December 31, 2021. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory. Costs incurred in connection with government research grants are recorded as research and development expense.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development of the Company.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statements of operations.</span></div> Stock-Based CompensationAll share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU is effective for annual periods beginning after December 15, 2021. The adoption of this standard has not materially impacted the Company’s condensed consolidated financial statements in 2022.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new pronouncement is not yet effective but may impact the Company's unaudited condensed consolidated financial statements in the future.</span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently issued amendments to ASU 2016-13, which have the same </span></div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance is effective for fiscal years beginning after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its unaudited condensed consolidated financial statements.</span> BASIC AND DILUTED NET LOSS PER SHARE<div style="margin-bottom:9pt;padding-right:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards and warrants.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294,407 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912,534 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294,407 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912,534 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 949884 531946 54250 18862 1290273 2361726 2294407 2912534 INVESTMENTS<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments consist of the following at June 30, 2022 and December 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at June 30, 2022</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:37.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments are classified as available for sale as of June 30, 2022 and December 31, 2021.</span></div> <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments consist of the following at June 30, 2022 and December 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at June 30, 2022</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:37.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 7008000 0 30000 6978000 7008000 0 30000 6978000 10669000 0 8000 10661000 10669000 0 8000 10661000 FAIR VALUE MEASUREMENTS<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets classified as Level 2 at June 30, 2022 and December 31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurements at reporting date using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets for  identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable  inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurements at reporting date using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets for  identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable  inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets between category levels during the three and six months ended June 30, 2022 and the three and six months ended June 30, 2021.</span></div> <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurements at reporting date using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets for  identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable  inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurements at reporting date using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets for  identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable  inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,539 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2061000 0 0 2061000 0 6978000 0 6978000 2061000 6978000 0 9039000 4878000 0 0 4878000 0 10661000 0 10661000 4878000 10661000 0 15539000 ACCRUED EXPENSES<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following at:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field trials and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following at:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field trials and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 381000 452000 61000 71000 267000 264000 215000 97000 135000 252000 1059000 1136000 STOCK-BASED COMPENSATION<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expense Information for Employee and Non-Employee Stock Awards</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors of $488 and $1,011 for the three and six months ended June 30, 2022 and $415 and $739 for the three and six months ended June 30, 2021. At June 30, 2022, there was approximately $4,009 of unvested awards not yet recognized as compensation expense.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense related to unvested stock awards is expected to be recognized over a remaining weighted average period of 2.80 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity for the six months ended June 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,849.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,884 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of the Company's 2018 Stock Option and Incentive Plan ("2018 Stock Plan"), effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of 244,092 shares and 166,702 shares, respectively, to the 2018 Stock Plan, which represented 5% of the Company's outstanding common stock on the day prior to each increase. At its annual meeting of stockholders on May 24, 2021, stockholders approved an amendment to the 2018 Stock Plan to add 300,000 more shares to the plan. As of June 30, 2022, 29,964 shares remain available to be awarded from the 2018 Stock Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock compensation expense for restricted stock units ("RSUs") on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date fair market value. As RSUs vest, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount from the common stock issuable at the vest date. During the six months ended June 30, 2022, 9,430 employee RSUs vested, of which 2,952 common shares with a total market value of $13 were withheld to pay employee tax withholding.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the six months ended June 30, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -488000 1011000 415000 739000 4009000 P2Y9M18D <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity for the six months ended June 30, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,849.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,884 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 722765 19.22 227224 3.85 105 5849.14 949884 14.90 318699 30.12 244092 166702 0.05 300000 29964 9430 2952 13000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the six months ended June 30, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 9430 54250 9430 54250 P0Y4M9D LEASES<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity Analysis of Lease Liabilities</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At June 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.710%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (July to December)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Short-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Long-term lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quantitative Disclosure of Lease Costs</span></div><div style="margin-bottom:3pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>   June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>  June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information as of:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During 2016, the Company entered into a lease agreement, as amended, for its headquarters pursuant to which the Company leases 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease agreement will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for certain tenant improvements that resulted in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The CJ sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,427 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 7,800 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. YOI's leases for these facilities expire on various dates through May 2023.</span></div> At June 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.710%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (July to December)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Short-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Long-term lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table> 367000 749000 771000 793000 747000 3427000 512000 2915000 544000 2371000 <div style="margin-bottom:3pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>   June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>  June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information as of:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 151000 151000 303000 303000 183000 169000 332000 326000 153000 146000 295000 320000 181000 174000 340000 309000 P4Y4M24D P4Y10M24D 0.0725 0.0725 22213 229000 9874 3427000 103000 7800 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. The Company is paying Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $63 remains outstanding as of June 30, 2022. As part of the agreement, the Company has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. The current agreement terminates automatically on its second anniversary unless terminated earlier in accordance with the terms of the agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with the University of Missouri ("UM")</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops. Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production. The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products. The Company or UM may terminate the license agreement in accordance with the terms of the agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Leases</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026. See Note 8.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of June 30, 2022 and December 31, 2021, the Company did not have significant liabilities recorded for guarantees.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of June 30, 2022 and December 31, 2021.</span></div> 31000 P2Y 250000 63000 P2Y GEOGRAPHIC INFORMATION<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below. Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 103000 0 103000 174000 0 174000 252000 0 252000 331000 39000 370000 752000 143000 895000 896000 53000 949000 CAPITAL STOCK AND WARRANTS<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Public Offerings</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of $0.01 par value preferred stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding outstanding warrants to purchase common stock as of June 30, 2022:</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:48.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Issuable Upon Exercise of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price Per Share of Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Public Offering - Series B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Private Placement - Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017 Public Offering - Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2017 Registered Direct Offering</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 19, 2022, 1,071,453 Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued. During the six months ended June 30, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing $3,856 in cash proceeds. During the six months ended June 30, 2022, no warrants were exercised by warrant holders.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><div style="margin-bottom:3pt;padding-right:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:66.213%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of common shares reserved for future issuance</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294,407 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,921 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 1040000 12.25 12740000 747000 5000000 0.01 The following table summarizes information regarding outstanding warrants to purchase common stock as of June 30, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:48.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Issuable Upon Exercise of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price Per Share of Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Public Offering - Series B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Private Placement - Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017 Public Offering - Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 21, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2017 Registered Direct Offering</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table> 395528 8.00 718750 8.00 160975 90.00 14270 201.60 750 116.00 1290273 1071453 481973 3856000 <div style="margin-bottom:3pt;padding-right:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:66.213%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of common shares reserved for future issuance</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294,407 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,921 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 949884 722765 54250 9430 1290273 2361726 2294407 3093921 EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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͈#GB4R4$GF5(;]=)]C8Y1:Y'5\-B4. /DJW&[1X[ %W.TAV"GD[O!JUV(")HN& MR193)!D^-0C[*.S=/( M* G,I]0D%=;* 59JUTK=Y.I>U.=@V_'E2(:P9Y[=2L)4#>-&57"S,Z+U\Z6Z M%V!;/=#HY[-20N^#X*VT0G^2#ER+H7?(=XLW]-^EG\I6F^*6(8X05@&%42A" MO6)@DRE)!3 0"PL^OKL% M'VZ^? &?WGT&7_[M\O.[\TIJFU=Q*,GNIF(?U_C8;-9OMF:R_M=F M%A]H=)"I>URA9KZ>>*JC*R4U0=C+7Z7Q4)ID6 I%)(-$$KV$=8>AY9M9R@:^59#Z]#/=I[,N%<*OM M8?T#]ZFUX_RW]R&WZ2GD=/).;_J7S^^G,YE?T:6\6^3/DT3Q(,%9".,X1!#% M-(&4!RG,1!(JHG_'$+:9H ?:']L4K40$I8R@$=)NOAY"\/B,]8!+W]MF)TBL M)^X)Q?=,W4+RG^X63S_K-ZM9J_^RF:R'VAMDNIY0IIFPIQ[K-SC!!(+R2<#C MD)M3L@SC&"*919!FB,- )I@@B041K(_(A++WL4WW4J@RK545EN"8R\H->SL4G M_65^U-_JV\4#GJ/K;>Y)_-^K)>5M993*[H;&;B_QNS2?U@,4%9&(8T#*%Q MGM1;V!A#*@@S_TPBG. T"NE$+U9L8 M%_--,D[]0&L%!XUBW;?$YXZM'<,/.%Y]VZJ-)F88&M/8(@>ED!?M#?2F\&FE MDDEQLAZKY@V/:4T\X>N)\,^59E!N]P3=2QKWU:P;8Y>^\/GSY+1$AOI@.2IE9!*ILFQ[;E_>VG+X>KK!^"Y3A?=5.V9\KY M[>.U<1GX)8T=]TO#?Q]V&VOQCOJ/5/CWESW[2(I:Z6;%/A& M2_W3)7B62[!1]*).A&\JK8*6LOYC?(<=(\\!PP,)_RK1Q\,.S*%0YH&E.",^ MTIQ0I7B[,JF9JT[*W,Z?M8#YE&LARZ=*2([3[(JDSQ!.9QF&C^[L M"M/>P,_.C74THNK)/2U+%)O$]Y7#_IV@=K27ND'P+YMD2^P MVY+3HW'Q-!B^#(='>AK6*'A:Y1V#G\4K[BY^M:7P^=UW?F].->9.9Z(B%=&8 M$<@0#R$*(P4QQPE$,4NH_E%(,+?U\=O7P=@XHI$1-$("(Z6]E]]>$(\3@0]H M^M["N*'BY.AW3/5.GGY[&QS,U>^8.FU?OZ//=?7/_2SOIB:KQ'Q9?G[7YU=1]T#S_7DW7:B*&'KJOYHW5,5)@&2QKV7 M(P)1DB#(!,&0)"B(& XP3I))9;7^LJ3YTM(^,HST+K/JI0[]3;"VEP1=@N6] M!$Q_&O/R,F"ARA\T]P!#5,GU]*7$A&9!H!BD7"\K)ML63M_SBQU,WV>^8 M#>7[Z4GJ<;F#^AT*9P]1S]U[O2.JW!L_RF_EKXH)PI0*$3.8<)3JXU!&( M1 M!+G$BC'!58R=3)]VW8[MD'3P%D@O/?JCG,LR=SKX-EW>U[]8*"7SDH'F M:WZ@GR_.<0BU'+>SKHG.&(U7O!>JI+X 6N[JB?YO@0X U>^US\M.QW#/

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end

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end XML 57 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 134 226 1 false 35 0 false 6 false false R1.htm 0001001 - Document - Cover Sheet http://www.yield10bio.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED Sheet http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED Sheet http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED Sheet http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED Sheet http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 2101101 - Disclosure - ACCOUNTING POLICIES Sheet http://www.yield10bio.com/role/ACCOUNTINGPOLICIES ACCOUNTING POLICIES Notes 8 false false R9.htm 2106102 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 9 false false R10.htm 2108103 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE Sheet http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARE BASIC AND DILUTED NET LOSS PER SHARE Notes 10 false false R11.htm 2111104 - Disclosure - INVESTMENTS Sheet http://www.yield10bio.com/role/INVESTMENTS INVESTMENTS Notes 11 false false R12.htm 2114105 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 2117106 - Disclosure - ACCRUED EXPENSES Sheet http://www.yield10bio.com/role/ACCRUEDEXPENSES ACCRUED EXPENSES Notes 13 false false R14.htm 2120107 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.yield10bio.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 14 false false R15.htm 2124108 - Disclosure - LEASES Sheet http://www.yield10bio.com/role/LEASES LEASES Notes 15 false false R16.htm 2129109 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 2131110 - Disclosure - GEOGRAPHIC INFORMATION Sheet http://www.yield10bio.com/role/GEOGRAPHICINFORMATION GEOGRAPHIC INFORMATION Notes 17 false false R18.htm 2134111 - Disclosure - CAPITAL STOCK AND WARRANTS Sheet http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTS CAPITAL STOCK AND WARRANTS Notes 18 false false R19.htm 2202201 - Disclosure - ACCOUNTING POLICIES (Policies) Sheet http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 2303301 - Disclosure - ACCOUNTING POLICIES (Tables) Sheet http://www.yield10bio.com/role/ACCOUNTINGPOLICIESTables ACCOUNTING POLICIES (Tables) Tables http://www.yield10bio.com/role/ACCOUNTINGPOLICIES 20 false false R21.htm 2309302 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables) Sheet http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARETables BASIC AND DILUTED NET LOSS PER SHARE (Tables) Tables http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARE 21 false false R22.htm 2312303 - Disclosure - INVESTMENTS (Tables) Sheet http://www.yield10bio.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.yield10bio.com/role/INVESTMENTS 22 false false R23.htm 2315304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTS 23 false false R24.htm 2318305 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.yield10bio.com/role/ACCRUEDEXPENSESTables ACCRUED EXPENSES (Tables) Tables http://www.yield10bio.com/role/ACCRUEDEXPENSES 24 false false R25.htm 2321306 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.yield10bio.com/role/STOCKBASEDCOMPENSATION 25 false false R26.htm 2325307 - Disclosure - LEASES (Tables) Sheet http://www.yield10bio.com/role/LEASESTables LEASES (Tables) Tables http://www.yield10bio.com/role/LEASES 26 false false R27.htm 2332308 - Disclosure - GEOGRAPHIC INFORMATION (Tables) Sheet http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONTables GEOGRAPHIC INFORMATION (Tables) Tables http://www.yield10bio.com/role/GEOGRAPHICINFORMATION 27 false false R28.htm 2335309 - Disclosure - CAPITAL STOCK AND WARRANTS (Tables) Sheet http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSTables CAPITAL STOCK AND WARRANTS (Tables) Tables http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTS 28 false false R29.htm 2404401 - Disclosure - ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails ACCOUNTING POLICIES - Additional Information (Details) Details 29 false false R30.htm 2405402 - Disclosure - ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) Sheet http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) Details 30 false false R31.htm 2407403 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Sheet http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Details http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION 31 false false R32.htm 2410404 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details) Sheet http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails BASIC AND DILUTED NET LOSS PER SHARE (Details) Details http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARETables 32 false false R33.htm 2413405 - Disclosure - INVESTMENTS (Details) Sheet http://www.yield10bio.com/role/INVESTMENTSDetails INVESTMENTS (Details) Details http://www.yield10bio.com/role/INVESTMENTSTables 33 false false R34.htm 2416406 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 34 false false R35.htm 2419407 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails ACCRUED EXPENSES (Details) Details http://www.yield10bio.com/role/ACCRUEDEXPENSESTables 35 false false R36.htm 2422408 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails STOCK-BASED COMPENSATION (Details) Details http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONTables 36 false false R37.htm 2423409 - Disclosure - STOCK-BASED COMPENSATION - RSU Activity (Details) Sheet http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails STOCK-BASED COMPENSATION - RSU Activity (Details) Details 37 false false R38.htm 2426410 - Disclosure - LEASES - Narrative (Details) Sheet http://www.yield10bio.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 38 false false R39.htm 2427411 - Disclosure - LEASES - Maturity Analysis of Lease Liabilities (Details) Sheet http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails LEASES - Maturity Analysis of Lease Liabilities (Details) Details 39 false false R40.htm 2428412 - Disclosure - LEASES - Quantitative Disclosure of Lease Costs (Details) Sheet http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails LEASES - Quantitative Disclosure of Lease Costs (Details) Details 40 false false R41.htm 2430413 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIES 41 false false R42.htm 2433414 - Disclosure - GEOGRAPHIC INFORMATION (Details) Sheet http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails GEOGRAPHIC INFORMATION (Details) Details http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONTables 42 false false R43.htm 2436415 - Disclosure - CAPITAL STOCK AND WARRANTS - Narrative (Details) Sheet http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails CAPITAL STOCK AND WARRANTS - Narrative (Details) Details 43 false false R44.htm 2437416 - Disclosure - CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details) Sheet http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details) Details 44 false false R45.htm 2438417 - Disclosure - CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details) Sheet http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details) Details 45 false false All Reports Book All Reports yten-20220630.htm ex-311x20220630.htm ex-312x20220630.htm ex-321x20220630.htm yten-20220630.xsd yten-20220630_cal.xml yten-20220630_def.xml yten-20220630_lab.xml yten-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "yten-20220630.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 134, "dts": { "calculationLink": { "local": [ "yten-20220630_cal.xml" ] }, "definitionLink": { "local": [ "yten-20220630_def.xml" ] }, "inline": { "local": [ "yten-20220630.htm" ] }, "labelLink": { "local": [ "yten-20220630_lab.xml" ] }, "presentationLink": { "local": [ "yten-20220630_pre.xml" ] }, "schema": { "local": [ "yten-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 349, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 19, "keyStandard": 207, "memberCustom": 10, "memberStandard": 22, "nsprefix": "yten", "nsuri": "http://www.yield10bio.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.yield10bio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE", "role": "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARE", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - INVESTMENTS", "role": "http://www.yield10bio.com/role/INVESTMENTS", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117106 - Disclosure - ACCRUED EXPENSES", "role": "http://www.yield10bio.com/role/ACCRUEDEXPENSES", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120107 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - LEASES", "role": "http://www.yield10bio.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129109 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131110 - Disclosure - GEOGRAPHIC INFORMATION", "role": "http://www.yield10bio.com/role/GEOGRAPHICINFORMATION", "shortName": "GEOGRAPHIC INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134111 - Disclosure - CAPITAL STOCK AND WARRANTS", "role": "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTS", "shortName": "CAPITAL STOCK AND WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - ACCOUNTING POLICIES (Policies)", "role": "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies", "shortName": "ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED", "role": "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "yten:CostOfRevenueResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - ACCOUNTING POLICIES (Tables)", "role": "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESTables", "shortName": "ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables)", "role": "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARETables", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - INVESTMENTS (Tables)", "role": "http://www.yield10bio.com/role/INVESTMENTSTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318305 - Disclosure - ACCRUED EXPENSES (Tables)", "role": "http://www.yield10bio.com/role/ACCRUEDEXPENSESTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321306 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325307 - Disclosure - LEASES (Tables)", "role": "http://www.yield10bio.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332308 - Disclosure - GEOGRAPHIC INFORMATION (Tables)", "role": "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONTables", "shortName": "GEOGRAPHIC INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335309 - Disclosure - CAPITAL STOCK AND WARRANTS (Tables)", "role": "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSTables", "shortName": "CAPITAL STOCK AND WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - ACCOUNTING POLICIES - Additional Information (Details)", "role": "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails", "shortName": "ACCOUNTING POLICIES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED", "role": "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details)", "role": "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails", "shortName": "ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "role": "http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)", "role": "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i71ee6d5e8ba04cf8af03ff75889f50f6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - INVESTMENTS (Details)", "role": "http://www.yield10bio.com/role/INVESTMENTSDetails", "shortName": "INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i71ee6d5e8ba04cf8af03ff75889f50f6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i71ee6d5e8ba04cf8af03ff75889f50f6_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i20579c3f9c844ac1b5b84cdd723b8812_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - ACCRUED EXPENSES (Details)", "role": "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails", "shortName": "ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422408 - Disclosure - STOCK-BASED COMPENSATION (Details)", "role": "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "shortName": "STOCK-BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i65309221876647d8aedccc4baeb89ddd_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423409 - Disclosure - STOCK-BASED COMPENSATION - RSU Activity (Details)", "role": "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails", "shortName": "STOCK-BASED COMPENSATION - RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i65309221876647d8aedccc4baeb89ddd_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426410 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.yield10bio.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427411 - Disclosure - LEASES - Maturity Analysis of Lease Liabilities (Details)", "role": "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails", "shortName": "LEASES - Maturity Analysis of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428412 - Disclosure - LEASES - Quantitative Disclosure of Lease Costs (Details)", "role": "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails", "shortName": "LEASES - Quantitative Disclosure of Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic32040d4feab4f43932ad1bfc3a73039_D20201101-20201130", "decimals": null, "first": true, "lang": "en-US", "name": "yten:CollaborativeArrangementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430413 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic32040d4feab4f43932ad1bfc3a73039_D20201101-20201130", "decimals": null, "first": true, "lang": "en-US", "name": "yten:CollaborativeArrangementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433414 - Disclosure - GEOGRAPHIC INFORMATION (Details)", "role": "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails", "shortName": "GEOGRAPHIC INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ibe9cd1c637164ca5aaff965c787d45e6_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436415 - Disclosure - CAPITAL STOCK AND WARRANTS - Narrative (Details)", "role": "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "shortName": "CAPITAL STOCK AND WARRANTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i260ea60193b6435f8af267e7519e255c_D20220519-20220519", "decimals": "INF", "lang": "en-US", "name": "yten:ClassOfWarrantOrRightExpired", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437416 - Disclosure - CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details)", "role": "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails", "shortName": "CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438417 - Disclosure - CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details)", "role": "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails", "shortName": "CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "ic2ed873b478e45eca75cb86daac09240_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED", "role": "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i9e3346c4a9174d47a274c1fd9727e6a1_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED", "role": "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i5ae8f9290f704666a456b68b68d0a88a_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i5ae8f9290f704666a456b68b68d0a88a_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - ACCOUNTING POLICIES", "role": "http://www.yield10bio.com/role/ACCOUNTINGPOLICIES", "shortName": "ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106102 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "yten-20220630.htm", "contextRef": "i0e8812ef35f345cf8d713c9d5b3f6487_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.yield10bio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r161", "r264", "r267", "r497" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r161", "r264", "r267", "r497" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r157", "r206", "r207", "r264", "r265", "r458", "r494", "r495" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r157", "r206", "r207", "r264", "r265", "r458", "r494", "r495" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r158", "r159", "r264", "r266", "r496", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r158", "r159", "r264", "r266", "r496", "r512", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25", "r426" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r163", "r164" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r36", "r37", "r38", "r483", "r505", "r509" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r35", "r38", "r46", "r47", "r48", "r82", "r83", "r84", "r357", "r423", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r82", "r83", "r84", "r320", "r321", "r322", "r370" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Taxes paid on employees' behalf related to vesting of stock awards" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r278", "r324", "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive common stock excluded from the calculation of dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Leased area (in sq ft)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r12", "r78", "r137", "r147", "r153", "r180", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r353", "r358", "r383", "r424", "r426", "r465", "r481" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r24", "r78", "r180", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r353", "r358", "r383", "r424", "r426" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r374" ], "calculation": { "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r171" ], "calculation": { "http://www.yield10bio.com/role/INVESTMENTSDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r172" ], "calculation": { "http://www.yield10bio.com/role/INVESTMENTSDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized (Loss)" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r169", "r192" ], "calculation": { "http://www.yield10bio.com/role/INVESTMENTSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Accumulated Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r168", "r170", "r192", "r469" ], "calculation": { "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.yield10bio.com/role/INVESTMENTSDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Market Value", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r282", "r283", "r284", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r306", "r307", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r81", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r10", "r70" ], "calculation": { "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r71", "r464" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "verboseLabel": "Unrestricted cash and cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r65", "r70", "r72" ], "calculation": { "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r65", "r392" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r253", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise Price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r470", "r487" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r203", "r204", "r205", "r208", "r514" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total number of common shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r82", "r83", "r370" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r426" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock ($0.01 par value per share); 60,000,000 shares authorized at June 30, 2022 and December 31, 2021; 4,901,246 and 4,881,851 shares issued and outstanding\u00a0at June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44", "r52", "r473", "r489" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r197", "r198", "r346" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r118", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r121", "r122", "r123", "r124", "r381", "r382", "r513" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r74", "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r54" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of investment holdings" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r68", "r79", "r335", "r342", "r343", "r344" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r68", "r135" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r281", "r282", "r315", "r316", "r318", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r53", "r91", "r92", "r93", "r94", "r95", "r100", "r102", "r104", "r105", "r106", "r110", "r111", "r371", "r372", "r474", "r490" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r53", "r91", "r92", "r93", "r94", "r95", "r102", "r104", "r105", "r106", "r110", "r111", "r371", "r372", "r474", "r490" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r107", "r108", "r109", "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r392" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining recognition period (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Employee stock option", "verboseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r46", "r47", "r48", "r82", "r83", "r84", "r87", "r96", "r98", "r113", "r184", "r245", "r252", "r320", "r321", "r322", "r339", "r340", "r370", "r393", "r394", "r395", "r396", "r397", "r398", "r423", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r374", "r375", "r379" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r220", "r223", "r224", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r375", "r430", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r374", "r375", "r376", "r377", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r220", "r269", "r270", "r275", "r276", "r375", "r430" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted prices in active markets\u00a0for identical assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r220", "r223", "r224", "r269", "r270", "r275", "r276", "r375", "r431" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant\u00a0other observable\u00a0inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r220", "r223", "r224", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r375", "r432" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant unobservable inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r220", "r223", "r224", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r430", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r173", "r174", "r176", "r177", "r178", "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r222", "r243", "r360", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r532", "r533", "r534", "r535", "r536", "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r199", "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r50", "r137", "r146", "r149", "r152", "r155", "r462", "r471", "r475", "r492" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r80", "r97", "r98", "r136", "r331", "r341", "r345", "r493" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r45", "r329", "r330", "r332", "r333", "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r67" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r67" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Unbilled receivables" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (decrease) in stockholders' equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r179", "r491" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r175", "r463", "r477", "r511", "r539" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r414", "r416" ], "calculation": { "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost, net" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease costs and other information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Right-of-Use Assets" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturity analysis of lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r415" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Undiscounted future lease payments", "totalLabel": "Total undiscounted future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails", "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r415" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r415" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r415" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r415" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r415" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (July to December)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Amount of lease payments representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r78", "r148", "r180", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r354", "r358", "r359", "r383", "r424", "r425" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r78", "r180", "r383", "r426", "r466", "r485" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r29", "r78", "r180", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r354", "r358", "r359", "r383", "r424", "r425", "r426" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r69" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r39", "r42", "r48", "r51", "r69", "r78", "r86", "r91", "r92", "r93", "r94", "r97", "r98", "r103", "r137", "r146", "r149", "r152", "r155", "r180", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r372", "r383", "r472", "r488" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r85", "r86", "r87", "r88", "r89", "r90", "r93", "r99", "r110", "r166", "r167", "r181", "r182", "r183", "r184", "r185", "r186", "r320", "r321", "r322", "r337", "r338", "r339", "r340", "r347", "r348", "r349", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r400", "r401", "r402", "r403", "r404", "r405", "r418", "r419", "r420", "r421", "r422", "r423", "r459", "r460", "r461", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r137", "r146", "r149", "r152", "r155" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r409", "r416" ], "calculation": { "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r407" ], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r407" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of lease liabilities", "verboseLabel": "Short-term lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r407" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r406" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r413", "r416" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r412", "r416" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r351", "r352", "r356" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Change in foreign currency translation adjustment, net of income tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r40", "r43", "r351", "r352", "r356" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Effect of foreign currency translation and unrealized loss on investments", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r34", "r36" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Change in unrealized loss on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r63" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Taxes paid on employees' behalf related to vesting of stock awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r61" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15", "r229" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15", "r229" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15", "r426" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "verboseLabel": "Private offering" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r62" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r59" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-Term Investments", "terseLabel": "Proceeds from the maturity of short-term investments" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from warrants exercised" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r201", "r426", "r478", "r486" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "verboseLabel": "Identifiable long-lived assets" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r201", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Estimated Useful Lives of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r10", "r70", "r72", "r464", "r482" ], "calculation": { "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails", "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESScheduleofCashAndRestrictedCashDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r252", "r426", "r484", "r504", "r509" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r82", "r83", "r84", "r87", "r96", "r98", "r184", "r320", "r321", "r322", "r339", "r340", "r370", "r500", "r502" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r133", "r134", "r145", "r150", "r151", "r157", "r158", "r161", "r263", "r264", "r458" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r75", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Grant Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Geographic Information" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Gross proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Common stock issued in offering (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock price (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock units activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r72", "r464", "r482" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Restricted Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r55", "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of the geographic distribution of revenues and long-lived assets" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r49", "r160" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r277", "r279", "r282", "r283", "r284", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r306", "r307", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r286", "r302", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r13", "r15", "r16", "r76", "r114", "r115", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r238", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r14", "r15", "r16", "r226", "r227", "r228", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r253", "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Information with regard to outstanding warrants to purchase common stock" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r129", "r131", "r132", "r137", "r138", "r149", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "GEOGRAPHIC INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/GEOGRAPHICINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r139", "r140", "r141", "r142", "r143", "r144", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Awarded (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)", "terseLabel": "Shares vested in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted\u00a0Average Exercise\u00a0Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r282", "r283", "r284", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r306", "r307", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r285", "r308", "r309", "r310", "r311", "r314", "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares withheld for employee taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r23", "r467", "r468", "r480" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r410", "r416" ], "calculation": { "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r73", "r81" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r33", "r46", "r47", "r48", "r82", "r83", "r84", "r87", "r96", "r98", "r113", "r184", "r245", "r252", "r320", "r321", "r322", "r339", "r340", "r370", "r393", "r394", "r395", "r396", "r397", "r398", "r423", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r82", "r83", "r84", "r113", "r458" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r32", "r221", "r245", "r246", "r252" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock for warrant exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock for 401k match (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r245", "r252" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in connection with stock offering, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r245", "r252" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock for restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r33", "r245", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock for warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock for 401(k) match" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r245", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in connection with stock offering, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r15", "r16", "r245", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock for restricted units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r78", "r165", "r180", "r383", "r426" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r230", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r252", "r254", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "CAPITAL STOCK AND WARRANTS" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r411", "r416" ], "calculation": { "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r173", "r174", "r176", "r177", "r178", "r222", "r243", "r360", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r532", "r533", "r534", "r535", "r536", "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r269", "r476", "r510" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "Government securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/INVESTMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledContractsReceivable": { "auth_ref": [ "r457" ], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.", "label": "Unbilled Contracts Receivable", "terseLabel": "Unbilled receivables" } } }, "localname": "UnbilledContractsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r116", "r117", "r119", "r120", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleofCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r101", "r106" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Number of shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r100", "r106" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "sharesItemType" }, "yten_A410DowneyRoadAnd110GymnasiumPlaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "410 Downey Road And 110 Gymnasium Place [Member]", "label": "410 Downey Road And 110 Gymnasium Place [Member]", "terseLabel": "410 Downey Road and 110 Gymnasium Place" } } }, "localname": "A410DowneyRoadAnd110GymnasiumPlaceMember", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "yten_AccountsReceivableAfterAllowanceForCreditLossCurrentAndUnbilledContractsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current And Unbilled Contracts Receivable", "label": "Accounts Receivable, After Allowance For Credit Loss, Current And Unbilled Contracts Receivable", "terseLabel": "Accounts and unbilled receivables" } } }, "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentAndUnbilledContractsReceivable", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "yten_AccruedFieldTrialsAndRelatedExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Field Trials And Related Expenses, Current", "label": "Accrued Field Trials And Related Expenses, Current", "terseLabel": "Field trials and related expenses" } } }, "localname": "AccruedFieldTrialsAndRelatedExpensesCurrent", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "yten_AccruedLeaseCost": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Lease Cost", "label": "Accrued Lease Cost", "terseLabel": "Leased facilities" } } }, "localname": "AccruedLeaseCost", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "yten_CJCheilJedangCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CJ CheilJedang Corporation [Member]", "label": "CJ CheilJedang Corporation [Member]", "terseLabel": "CJ CheilJedang Corporation" } } }, "localname": "CJCheilJedangCorporationMember", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "yten_ChargeForCompanyCommonStockMatch": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The noncash charge representing the fair value of Company common stock issued by the company to participants in the Company's 401(k) plan as a matching contribution during the reporting period. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Charge for Company Common Stock Match", "terseLabel": "Charge for 401(k)\u00a0company common stock match" } } }, "localname": "ChargeForCompanyCommonStockMatch", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "yten_ClassOfWarrantOrRightExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant Or Right, Exercised", "label": "Class of Warrant Or Right, Exercised", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercised", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "yten_ClassOfWarrantOrRightExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant Or Right, Expired", "label": "Class of Warrant Or Right, Expired", "terseLabel": "Warrants expired (in shares)" } } }, "localname": "ClassOfWarrantOrRightExpired", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable", "label": "Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable", "terseLabel": "Collaborative agreement, quarterly research funding and option fees payable" } } }, "localname": "CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Research Funding And Option Fees Payable", "label": "Collaborative Arrangement, Research Funding And Option Fees Payable", "terseLabel": "Collaborative agreement, research funding and option fees payable" } } }, "localname": "CollaborativeArrangementResearchFundingAndOptionFeesPayable", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "yten_CollaborativeArrangementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Term", "label": "Collaborative Arrangement, Term", "terseLabel": "Collaborative agreement, term" } } }, "localname": "CollaborativeArrangementTerm", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "yten_CollaborativeArrangementTermOfOptionForLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Term Of Option For License Agreement", "label": "Collaborative Arrangement, Term Of Option For License Agreement", "terseLabel": "Collaborative agreement, term of option" } } }, "localname": "CollaborativeArrangementTermOfOptionForLicenseAgreement", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "yten_CostOfRevenueResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the expenses associated with internal research and development as well as research and development services conducted for others are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors; facility related expenses, depreciation and stock-based compensation related to employees and non-employees involved in the company's research and development, which also includes the costs related to revenue-producing contracts, which are recorded as research and development expenses, during the period by the entity.", "label": "Cost of Revenue Research and Development Expenses", "terseLabel": "Research and development" } } }, "localname": "CostOfRevenueResearchAndDevelopmentExpenses", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "yten_EmployeeAndDirectorsStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Employee And Directors Stock Options [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeAndDirectorsStockOptionsMember", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "yten_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "yten_IntellectualPropertyCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intellectual property costs.", "label": "Intellectual Property Costs Policy [Text Block]", "terseLabel": "Intellectual Property Costs" } } }, "localname": "IntellectualPropertyCostsPolicyTextBlock", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "yten_LeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Other Information [Abstract]", "label": "Lease, Other Information [Abstract]", "terseLabel": "Other information as of:" } } }, "localname": "LeaseOtherInformationAbstract", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/LEASESQuantitativeDisclosureofLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "yten_LesseeOperatingSubleaseSubleasedArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Sublease, Subleased Area", "label": "Lessee, Operating Sublease, Subleased Area", "terseLabel": "Subleased area (in sq ft)" } } }, "localname": "LesseeOperatingSubleaseSubleasedArea", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "areaItemType" }, "yten_MichiganStateUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Michigan State University [Member]", "label": "Michigan State University [Member]", "terseLabel": "Michigan State University" } } }, "localname": "MichiganStateUniversityMember", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/ACCOUNTINGPOLICIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "yten_NoncashLeaseExpenseIncome": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Lease Expense (Income)", "label": "Noncash Lease Expense (Income)", "terseLabel": "Non-cash lease expense" } } }, "localname": "NoncashLeaseExpenseIncome", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "yten_OperatingLeaseLiabilityNoncurrentExcludingLeaseIncludedOnBalanceSheet": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Liability, Noncurrent, Excluding Lease Included on Balance Sheet", "label": "Operating Lease Liability, Noncurrent, Excluding Lease Included on Balance Sheet", "verboseLabel": "Long-term lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrentExcludingLeaseIncludedOnBalanceSheet", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/LEASESMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "yten_PaymentTaxWithholdingShareBasedPaymentArrangementExcludingEmployerAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Tax Withholding, Share Based Payment Arrangement, Excluding Employer Amount", "label": "Payment Tax Withholding, Share Based Payment Arrangement, Excluding Employer Amount", "terseLabel": "Taxes paid on employees' behalf related to vesting of stock awards" } } }, "localname": "PaymentTaxWithholdingShareBasedPaymentArrangementExcludingEmployerAmount", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "monetaryItemType" }, "yten_PresidentialWayWoburnMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Presidential Way, Woburn, Massachusetts [Member]", "label": "Presidential Way, Woburn, Massachusetts [Member]", "terseLabel": "19 Presidential Way" } } }, "localname": "PresidentialWayWoburnMassachusettsMember", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "yten_ProceedsFromWarrantExercisesNet": { "auth_ref": [], "calculation": { "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Warrant Exercises, Net", "label": "Proceeds From Warrant Exercises, Net", "terseLabel": "Proceeds from warrants exercised" } } }, "localname": "ProceedsFromWarrantExercisesNet", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "yten_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering [Member]", "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSNarrativeDetails", "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" }, "yten_SeriesAWarrantExpiringDecember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Warrant Expiring December 2022 [Member]", "label": "Series A Warrant Expiring December 2022 [Member]", "terseLabel": "Series A Warrants - expiration December 2022" } } }, "localname": "SeriesAWarrantExpiringDecember2022Member", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" }, "yten_SeriesBWarrantExpiringMay2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Warrant Expiring May 2027 [Member]", "label": "Series B Warrant Expiring May 2027 [Member]", "terseLabel": "Series B Warrants - expiration May 2027" } } }, "localname": "SeriesBWarrantExpiringMay2027Member", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" }, "yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percent", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percent", "terseLabel": "Additional shares authorized percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/STOCKBASEDCOMPENSATIONDetails" ], "xbrltype": "percentItemType" }, "yten_WarrantExpiringJanuary2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Expiring January 2024 [Member]", "label": "Warrant Expiring January 2024 [Member]", "terseLabel": "Warrants - expiration January 2024" } } }, "localname": "WarrantExpiringJanuary2024Member", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" }, "yten_WarrantExpiringSeptember2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Expiring September 2024 [Member]", "label": "Warrant Expiring September 2024 [Member]", "terseLabel": "Warrants - expiration September 2024" } } }, "localname": "WarrantExpiringSeptember2024Member", "nsuri": "http://www.yield10bio.com/20220630", "presentation": [ "http://www.yield10bio.com/role/CAPITALSTOCKANDWARRANTSScheduleOfWarrantsIssuanceDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r417": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r463": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r477": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r511": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r528": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r529": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r530": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r531": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r532": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r533": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r534": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r535": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r536": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r537": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r538": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r539": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r540": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" } }, "version": "2.1" } ZIP 62 0001121702-22-000039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001121702-22-000039-xbrl.zip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